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ABSTRACT  
The differentiation of osteoblasts and bone marrow adipocytes are closely 
associated yet mutually exclusive processes that are essential for maintaining bone 
homeostasis. Various diseases have been shown to develop once the delicate balance 
between adipogenesis and osteoblastogenesis is disrupted. Investigating the underlying 
molecular mechanisms of the osteoblasto-adipogenic switch under osteoporotic 
conditions will facilitate our understanding of the pathogenesis of osteoporosis and may 
eventually lead to the development of clinical therapeutic approaches for this life-
threatening disease.  While changes in cell morphology and cytoskeletal integrity can 
alter pre-committed mesenchymal stem cell (MSC) differentiation of certain lineages, 
previous studies have shown that cellular morphological changes can affect the early 
commitment of pluripotent MSCs via modulation of Ras homolog gene family, member 
A (RhoA) activity. The RhoA pathway regulates actin polymerization to promote the 
incorporation of globular-actin (G-actin) into filamentous-actin (F-actin). Actin 
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polymerization releases G-actin bound myocardin-related transcription factors (MRTFs), 
which translocate to the nucleus and co-activate serum response factor (SRF) target gene 
expression. Exactly how the RhoA-actin-MRTF-SRF circuit is involved in the regulation 
of early commitment of MSCs remains poorly understood.  Here we show that global 
MRTFA knockout mice (MRTFA KO) exhibited lower body weight, shorter femur and 
tibia lengths, and decreased trabecular bone volume. Furthermore, bone marrow MSCs 
isolated from MRTFA KO mice showed increased adipogenesis and brown fat gene 
expression as well as compromised osteoblastogenic differentiation as compared to WT 
controls. Treatment of WT bone marrow MSCs with the SRF inhibitor, CCG1423, 
mimicked these effects in that the compound inhibited osteoblastogenesis and promoted 
adipogenesis. Over-expression of MRTFA or SRF inhibited adipogenesis and enhanced 
osteoblastogenesis in C3H/10T1/2 cell lines, whereas over-expression of dominant-
negative MRTFA or SRF variants had the opposite effects. In conclusion, our study 
identified MRTFA as a crucial regulator of skeletal homeostasis via regulating the 
balance between adipogenic and osteoblastogenic differentiation of the MSCs. Furthering 
our understanding of how the RhoA-actin-MRTFA-SRF circuit is involved in regulating 
the fate commitment of MSCs may ultimately lead to novel therapeutic strategies for 
treating osteoporosis and obesity.  
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INTRODUCTION 
Osteoporosis 
Osteoporosis is a skeletal disorder characterized by decreased bone mass and 
deterioration of bone microstructure, which leads to increased fragility fractures in 
patients even without severe trauma (NIH 2001, Raisz 2005, Rosen and Bouxsein 2006, 
Kling, Clarke et al. 2014, Montagnani 2014). It is an emerging public health burden 
affecting more than 10 million American adults and another 34 million people are 
considered at high risk of developing it due to low bone mass (Melton 2001). In the 
United States alone, approximately $17 billion was spent on health care for osteoporosis-
related mortality and morbidity in 2005 (Burge, Dawson-Hughes et al. 2007). The costs 
for combating osteoporosis are estimated to rise by 50% by 2025 due to the increasing 
cases of pathological fractures in patients above the age of 65 (Burge, Dawson-Hughes et 
al. 2007). 
Osteoporosis was first identified by the English surgeon Sir Astley Cooper in 
1822 who described this condition as “the lightness and softness that bones acquire in the 
most advanced stage of life… and this state of bone… favors much the production of 
fractures” (Cooper et al., 1822). Since then, more and more studies have led to a better 
understanding of the pathogenesis of osteoporosis. Genetic studies revealed the 
connection between osteoporosis and various growth factors, receptors and transcription 
factors. More than 30 genes (including estrogen receptor (ER), vitamin D receptor (VDR), 
collagen type 1α1 (COL1A1) and transforming growth factor-β1 (TGFB1)) are shown to 
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be important for maintaining bone mass in human osteoporosis clinical studies (Liu, Liu 
et al. 2003, Baldock and Eisman 2004). Osteoporosis induced fragility fractures in hip 
and spine often lead to chronic pain and immobility and it is very detrimental for the 
quality of life for aging patients (Montagnani 2014). In addition, severe medical 
complications such as thromboembolic disease or pneumonia can develop in long term 
immobile patients suffering from fragility fractures (Montagnani 2014).  
Low peak bone mass during growth, excessive bone resorption and inadequate 
bone formation during bone remodeling are the three basic pathogenic mechanisms for 
osteoporosis (Raisz 2005). In humans, the majority of bone mass accumulation happens 
during the ages of 12-18. If bone formation during this time is hindered by pathological 
conditions such as inadequate growth hormones, then lower primal bone mass will ensue 
in adult life and there will be a higher possibility for fragility fractures as the patients age 
(Recker and Heaney 1993). The pathology of this type of osteoporosis happened earlier 
in life during growth whereas the phenotype does not manifest itself until decades later. 
On the other hand, age-related osteoporosis often develops rapidly when patients are in 
their 50’s. The bone loss during aging is inevitable as bone resorption is much more 
active than formation during this stage of adult life (Brown and Rosen 2003). Post-
menopausal patients usually have more severe osteoporosis due to the activation of 
osteoclasts and the decline in osteoblast functions caused by a marked decrease in 
estrogen levels (Black, Greenspan et al. 2003, Howe, Shea et al. 2011). Long-term 
treatments for some chronic diseases also aggravate bone loss in patients, such as the use 
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of glucocorticoids or the thiazolidinediones (TZD) family of insulin sensitizers (Gimble, 
Robinson et al. 1996, Ali, Weinstein et al. 2005, Lane and Yao 2010).   
Current treatments for osteoporosis in clinical practice focus on inhibiting bone 
resorption and enhancing bone formation (Montagnani 2014). Bisphosphonates are the 
most commonly prescribed drugs for treating osteoporosis by inhibiting bone resorption. 
With a high affinity for bone and high efficiency in decreasing the fracture risks in 
patients, bisphosphonates are used widely in clinical practice (Cummings, Black et al. 
1998, Harris, Watts et al. 1999, Black, Thompson et al. 2000, McClung, Geusens et al. 
2001, Black, Delmas et al. 2007). However, long-term use of these drugs leads to 
osteonecrosis of the jaw amongst other undesirable side effects (Black, Schwartz et al. 
2006, Rizzoli, Akesson et al. 2011). Anabolic treatments promoting osteoblast function 
are also used clinically such as drugs enhancing parathyroid hormone (PTH) signaling 
(Horwitz, Tedesco et al. 2010) and wingless-int (Wnt) signaling (Baron and Hesse 2012) 
in bone. Unfortunately, these aforementioned treatments are not sufficient to maintain 
bone mass in severely osteoporotic patients. Novel therapeutic approaches for 
osteoporosis are needed for preventing fragility fractures and improving quality of life in 
an increasing aging population.  
 
Bone Remodeling 
 To fully understand the mechanism of osteoporosis caused by excessive bone 
resorption and inadequate bone formation, it is essential to understand the bone 
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remodeling process in the adult skeleton. To maintain the proper shapes, sizes and 
integrity, bone is constantly undergoing remodeling by replacing approximately 10% of 
the bone material annually (Lerner 2006). Bone remodeling is a complicated process, 
involving both bone formation by osteoblasts and bone resorption by osteoclasts 
(Hadjidakis and Androulakis 2006, Neumann and Schett 2007).  
 Bone remodeling occurs in both trabecular and cortical bone (Raisz 2005) and it 
starts with the activation of osteoclasts differentiation by nuclear factor κ B ligand 
(RANKL) expressed by pre-osteoblasts (Wada, Nakashima et al. 2006). When 
osteoclasts are fully differentiated, they secrete proteases and other factors that can digest 
mineralized bone (Hadjidakis and Androulakis 2006, Glass and Karsenty 2007).  After a 
reversal phase when the bone surface is occupied by differentiating osteoblast progenitors, 
the bone formation phase is initiated by bone matrix production followed by osteoblast 
maturation. Mature osteoblasts are then embedded in the mineralized bone for 
transformation into osteocytes (Hadjidakis and Androulakis 2006, Proff and Romer 2009). 
The resorption and reversal phases during the bone remodeling cycle are much shorter 
than the bone formation phase (Raisz 2005, Proff and Romer 2009). Therefore, a slight 
increase of bone remodeling rate will result in excessive bone resorption and eventually 
excessive bone loss.  
 It is intriguing that osteoblasts and osteoclasts collaborate so closely during bone 
remodeling by secreting factors to regulate the differentiation of one another (Raisz 2005, 
Matsuo and Irie 2008).  RANKL is expressed by pre-osteoblasts and resides on the 
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surface of these cells. The binding of osteoclast progenitors to RANKL is essential for 
the activation of signaling cascades regulating osteoclast differentiation (Wada, 
Nakashima et al. 2006). Tumor necrosis factor α (TNF-α), interleukin-1 (IL-1) and 
vitamin D have been shown to promote RANKL expression, whereas estrogens suppress 
it (Matsuo and Irie 2008). On the other hand, during bone resorption, growth factors 
including bone morphogenetic proteins (BMPs) released from degrading bone matrix are 
crucial for the osteoblast progenitor’s fate commitment (Matsuo and Irie 2008). 
 
Osteoporosis and Obesity 
 Obesity and osteoporosis are two major public health issues becoming more and 
more prevalent in recent years. Although these two diseases appear to develop in 
different ways, previous investigations revealed common characteristics between them 
such as genetic predisposition and environmental factors (Rosen and Bouxsein 2006). 
The underlying mechanism these two conditions share is the dysregulation of a common 
progenitor cell (Rosen and Bouxsein 2006, Cao 2011). The relationship between 
osteoporosis and obesity is a very active area of research since potential drugs targeting 
the common pathological mechanisms can be developed for treating these diseases 
simultaneously (Rosen and Bouxsein 2006, Cao 2011, Colaianni, Brunetti et al. 2014).  
 Obesity is a condition defined as having excessive body fat accumulation 
[characterized by a body mass index (BMI) ≥ 30 kg/m2] and it often associates with 
several metabolic co-morbidities (WHO 2000).  Obesity is caused by excessive energy 
6 
 
intake and inadequate energy expenditure (Ogden, Carroll et al. 2006, Bessesen 2008). 
The number of obese patients has doubled since 1980 and about 33% of American adults 
are obese (Bessesen 2008, Cao 2011). Obesity associated co-morbidities including 
hypertension, type II diabetes, dyslipidemia and coronary heart diseases are also leading 
causes of mortality (Messerli, Christie et al. 1981). In the United States, the healthcare 
expenditure related to obesity is approximately $100 billion per year (Wolf and Colditz 
1998). With increasing global prevalence and rising adolescence obesity, treating obesity 
and its associated co-morbidites will be a tremendous burden on the healthcare system 
(Bessesen 2008).   
 Various studies are aiming to understand the connection between obesity and 
osteoporosis. Traditionally, obesity is considered a positive factor for maintaining bone 
mass due to the excessive mechanical loading conferred to the bone (David, Martin et al. 
2007, Sen, Xie et al. 2008). However, recent evidence contradicted this notion by 
demonstrating that the obese condition is detrimental to bone health (Goulding, Taylor et 
al. 2000, Cao, Sun et al. 2010). Obesity promotes excessive bone loss via various 
mechanisms. Since adipocytes and osteoblasts are originated from a common progenitor 
mesenchymal stem cell (MSC), obesity may induce adipogenesis and inhibit 
osteoblastogenesis in the bone marrow, thereby inhibiting bone formation (Beresford, 
Bennett et al. 1992). Obesity induced inflammation increases the levels of circulating 
cytokines and leads to the enhancement of osteoclast activity (Wellen and Hotamisligil 
2003, Mundy 2007), thus promoting excessive bone loss in obese individuals (Cao 2011).  
In addition, high levels of leptin and decreased adiponectin secretion by adipose tissue in 
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obese patients appear to impair bone formation directly and indirectly through up-
regulating cytokine levels systemically (Hamrick, Pennington et al. 2004). Understanding 
the underlying connection between obesity and osteoporosis may facilitate identification 
of new drug targets that can inhibit adipogenesis and enhance osteoblastogenesis at the 
same time.  
 
Multipotent Mesenchymal Stem Cells (MSCs) 
MSCs are multipotent bone marrow stromal cells that possess the ability to self-
renew and develop into different lineages (Caplan and Bruder 2001, Jackson, Nesti et al. 
2012). Given the appropriate milieu of growth factors and microenvironment, MSCs can 
differentiate into chondrogenic, adipogenic, myogenic or osteoblastogenic lineages 
(Figure 1) (Aubin 1998, Chamberlain, Fox et al. 2007). Multiple signaling pathways and 
regulatory factors are reported to strictly regulate commitment and terminal 
differentiation of MSCs to each of these lineages; however the molecular mechanisms 
underlying the switches between them remain to be investigated (Caplan and Bruder 
2001, Chamberlain, Fox et al. 2007).  
MSCs are very scarce in the total cells population in the bone marrow, consisting 
about 0.001-0.01% of the total cells (Pittenger, Mackay et al. 1999). Despite that MSCs 
were first identified in the bone marrow stromal fraction, they can also be isolated from 
skeletal muscle and adipose tissue according to recent reports (Levi and Longaker 2011, 
James, Zara et al. 2012, Mizuno, Tobita et al. 2012). The perivascular stromal fraction of 
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adipose provided a more accessible source for MSCs that can potentially be used in tissue 
engineering (Crisan, Yap et al. 2008, James, Zara et al. 2012, Corselli, Crisan et al. 2013).  
 
Figure 1. MSCs are multipotent bone marrow stromal cells that possess the ability 
to self-renew and develop into different lineages. 
Given the appropriate milieu of growth factors and micro-environment, MSCs can 
differentiate into chondrogenic, adipogenic, myogenic or osteoblastogenic lineages. Each 
of these differentiation processes is strictly regulated to ensure to the proper development 
of these cells so that they can serve specialized functions in different tissues.  
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Adipogenesis 
Adipogenesis of MSCs can be roughly separated into two phases: determination 
phase and terminal differentiation phase. During the determination phase, MSCs commit 
to the adipose lineage with a shift in gene expression but without morphological 
differentiation (Muruganandan, Roman et al. 2009). During the terminal differentiation 
phase, preadipocytes undergo morphological changes (round up) to accommodate new 
functions such as lipid synthesis and storage. Lipid droplets will form during this phase 
and the mature adipocytes also secrete an array of adipokines (Rosen, Walkey et al. 2000, 
Rosen and MacDougald 2006).  
Investigations of the transcriptional cascade of adipogenesis have revealed several 
essential factors for different stages of adipocyte differentiation. The initiation of the 
adipogenesis starts with the induction of the early regulating factors, two members of the 
CCAAT enhancer binding protein (C/EBP) family, C/EBPβ and C/EBPδ. These two 
C/EBPs are expressed earlier than C/EBPα and peroxisome proliferator-activated 
receptor γ (PPARγ) and they regulate the expression of C/EBPα and PPARγ (Cao, Umek 
et al. 1991, Yeh, Cao et al. 1995). Upon induction by C/EBPs, PPARγ hetero-dimerizes 
with retinoid X receptor (RXR) and turns on the adipogenic transcription program to 
initiate adipocyte differentiation (Farmer 2006, Ali, Hochfeld et al. 2013). PPARγ and 
C/EBPα then activate the expression of each other in a positive feedback loop to maintain 
the expression of both genes in mature adipocytes. They also activate a variety of 
adipogenic genes that are important for adipocyte metabolic functions (Farmer 2006, 
Vernochet, Peres et al. 2009).  
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It is widely accepted that PPARγ expression is both sufficient and necessary for 
the commitment and differentiation phases of adipogenesis (Farmer 2006). Studies from 
transgenic mice of PPARγ confirmed its central role in adipogenesis. Knocking out 
PPARγ in white adipose tissue (WAT) leads to severe lipodystrophy in mice and these 
mice do not survive due to the failure to form adipose tissue (Koutnikova, Cock et al. 
2003). 
 
Osteoblastogenesis 
The osteoblast differentiation starts with commitment of progenitor cells and 
differentiation of pre-osteoblasts (Chamberlain, Fox et al. 2007). These cells form mature 
and functional osteoblasts which would eventually embed in mineralized bone as 
osteocytes (Neve, Corrado et al. 2011) The transcription factor Runt-related transcription 
factor 2 (Runx2) is indispensable for osteoblast differentiation (Komori, Yagi et al. 1997). 
Signaling pathways such as Wnt/β-catenin and the TGFβ/BMP pathways are also very 
important in regulating osteoblastogenic transcription factors (Hogan 1996, Gaur, 
Lengner et al. 2005). 
 Previous studies showed that Runx2 null mutant mice fail to form any bone due to 
the ablation of osteoblast differentiation (Komori, Yagi et al. 1997). Ectopically 
expressing Runx2 in non-osteoblastic cells is sufficient to activate osteoblast protein 
including osteocalcin, osteopontin, alkaline phosphatase and type I collagen (Ducy, 
Zhang et al. 1997). Runx2 is the central transcription factor for osteoblast differentiation. 
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In addition, osterix, a zinc finger containing transcription factor is also shown to be 
critical for osteoblastogenesis. Osterix-null mice showed a similar phenotype to Runx2 
null mice: an absence of bone formation due to blockage of osteoblast differentiation 
(Nakashima, Zhou et al. 2002). Although the osterix null and WT mice have similar 
levels of Runx2 transcription, the bone formation was completely inhibited in the osterix 
null mice. In Runx2 null mice, however, there is a complete abolishment of osterix 
transcription, which suggests osterix is acting downstream of Runx2 in the 
osteoblastogenesis transcription cascade (Nakashima, Zhou et al. 2002, Nakashima and 
de Crombrugghe 2003).  
 
The Balance between Adipogenesis and Osteoblastogenesis 
Adipogenesis and osteoblastogenesis are mutually exclusive yet closely 
associated processes during MSC development in the bone marrow. The delicate balance 
between two processes is essential for the maintenance of bone homeostasis. Once the 
precisely regulated balance between adipogenesis and osteoblastogenesis is disturbed, 
various metabolic-related diseases develop (James 2013).  
 Because adipocytes and osteoblasts are originated from the same bone marrow 
MSC progenitor, the conditions or agents that inhibit osteogenesis will promote 
adipogenesis and vice versa (Ali, Weinstein et al. 2005, David, Martin et al. 2007, Sen, 
Xie et al. 2008). For example, in age related osteoporosis, there is often an infiltration of 
adipose contents in the bone marrow due to a switched balance between adipocytes and 
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osteoblast formation (Meunier, Aaron et al. 1971, Rosen and Bouxsein 2006). On the 
other hand, the pharmacologic therapy for osteoporosis is shown to inhibit fat formation 
besides maintaining bone mass. In post-menopausal osteoporotic patients treated with sex 
hormone replacement therapy, there is also a reversal of menopause-related obesity in 
addition to inhibition of bone loss (Manson and Martin 2001, Sorensen, Rosenfalck et al. 
2001).   
Secondary osteoporosis is frequently observed in type II diabetic patients treated 
with Avandia, a member of the TZD family of insulin sensitizers and PPARγ agonists, 
resulting in an infiltration of adipocytes in the bone marrow in both males and females 
(Rzonca, Suva et al. 2004, Ali, Weinstein et al. 2005). The excessive adiposity in this 
condition is caused by the dysregulation of early MSC commitment leading to a switch 
from the osteoblastogenic to adipogenic lineages induced by TZDs through PPARγ 
activation (Lecka-Czernik, Moerman et al. 2002, Lazarenko, Rzonca et al. 2006). The 
long-term use of glucocorticoids has also been demonstrated to accelerate bone 
remodeling and enhance bone marrow adiposity and obesity (de Gregorio, Lacativa et al. 
2006, Faienza, Brunetti et al. 2009, Brunetti, Faienza et al. 2013, Ventura, Brunetti et al. 
2013). These findings further confirmed the reverse relationship between adipogenesis 
and osteogenesis.   
On the other hand, activating mutations of lipoprotein related receptor 5 (LRP5), a 
co-receptor for Wnt signaling pathway, leads to higher bone mass formation in humans 
(Boyden, Mao et al. 2002, Little, Carulli et al. 2002, Van Wesenbeeck, Cleiren et al. 
13 
 
2003). Qiu and coworkers showed that the biopsies of iliac bones from high bone mass 
individuals exhibited significantly enhanced bone mass but decreased fat mass (Qiu, 
Andersen et al. 2007). They further confirmed this finding with cell lines harboring LRP5 
mutations and showed that different levels of LRP5- Wnt signaling activation leads to 
different osteoblast and adipocyte differentiation abilities (Qiu, Andersen et al. 2007). 
These discoveries are consistent with the reverse correlation of adipogenesis and 
osteoblastogenesis demonstrated in osteoporosis patients as described before (Rosen and 
Bouxsein 2006).  
Interestingly, several pathways have been shown to both positively regulate 
osteoblastogenesis and adipogenesis. BMPs and insulin like growth factor (IGF) 
signaling are well documented to induce both adipogenic and osteoblastogenic 
differentiation in MSCs (Wabitsch, Hauner et al. 1995, Chen, Ji et al. 1998, Kang, Song 
et al. 2009, Xian, Wu et al. 2012). The mechanisms that dictate MSCs commitment to 
one lineage versus the other when activated by common positive regulator are not well 
characterized.  Our hypothesis is that cytoskeletal signaling is involved in controlling 
MSCs fate commitment to adipose versus osteoblastogenic lineage by dictating which 
transcription cascades will be turned on by BMP signaling.  
In conclusion, adipogenesis and osteoblastogenesis are reversely correlated 
processes in the bone marrow and the balance between them is essential for maintaining 
bone homeostasis (Figure 2). Studying the mechanism of the regulation of MSCs fate 
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commitment may provide insights for drug targets that enhance osteoblastogenesis and 
inhibit adipogenesis simultaneously.  
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Figure 2. A brief summary of signaling pathways regulating the fate commitment of 
MSCs to adipose versus osteoblastic lineages. 
 The signaling pathways regulating the fate commitment of MSCs to adipose 
versus osteoblastic lineages are summarized in the scheme below. BMPs and IGF1 
activate both adipogenesis and osteoblastogenesis. Wnt signaling and estrogen stimulate 
osteoblastogenesis but inhibit adipogenesis; while the TZDs and glucocorticoids (GCs) 
have the opposite effects. BMPs induce osteoblastogenesis through activating Smad 
signaling, which subsequently turns on the osteoblastogenic transcriptional cascade 
(Runx2 and osterix activate various osteoblastic proteins). Adipogenesis is initiated by 
the activation of PPARγ and C/EBPα by C/EBPβ and C/EBPδ, which act in a positive 
feedback loop to maintain one another’s expression, thereby turning on the expression of 
various adipogenic proteins.  
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Bone Morphogenetic Proteins (BMPs) Signaling in Adipogenesis and 
Osteoblastogenesis 
BMPs belong to the TGFβ superfamily, which is a large group of growth factors 
that includes about 50 genes (Ducy and Karsenty 2000, Chen, Deng et al. 2012). BMPs 
were first discovered in 1965 as osteo-inductive factors isolated from demineralized bone 
matrix. With the cloning of BMP2 and BMP4 in 1988 (Wozney, Rosen et al. 1988), 
multiple studies have been conducted to elucidate the function of the BMPs in skeletal 
tissue repair. As of 2005, BMP2 and BMP7 have already been approved for clinical uses 
to facilitate bone fractures healing in several countries (Reddi 2005).  
BMPs are essential in embryogenesis, cartilage development and bone formation 
(Hogan 1996, Ducy and Karsenty 2000, Luu, Song et al. 2007). Knocking out BMPs in 
mice results in severe skeletal defects during development (Hogan 1996, Zhao 2003). In 
vitro studies also showed that BMPs promote osteoblastogenesis in myoblasts by up-
regulating various osteoblastogenic proteins such as Runx2, osterix, alkaline phosphatase 
and osteocalcin (Katagiri, Imada et al. 2002, Zhao, Katagiri et al. 2006).  
BMPs induce osteoblast differentiation through a small mothers against 
decapentaplegic (Smad) dependent pathway (Derynck and Zhang 2003, Shi and 
Massague 2003, Guo and Wu 2012). Secreted dimers of BMPs bind cooperatively to the 
heterodimeric complex of type I and type II BMP receptors (two transmembrane 
serine/threonine kinase receptors). The phosphorylated type I receptor kinase then 
activates Smad proteins (Smad 1/5/8) via phosphorylation. Phosphorylated Smad1/5/8 
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binds with Smad4 to form a heterodimeric complex for nuclear translocation 
(Kretzschmar, Liu et al. 1997). This complex interacts directly with Runx2, the central 
transcription factor for the osteoblastogenesis cascade, and regulates osteoblast gene 
expression (Xiao, Gopalakrishnan et al. 2002, Phimphilai, Zhao et al. 2006).  
On the other hand, BMPs are also important for adipogenesis in the MSCs. 
Several lines of evidence have shown that BMP2, BMP4 and BMP7 bind cooperatively 
with other factors, can induce adipogenic differentiation through the activation of Smad 
signaling (Wang, Israel et al. 1993, Bowers, Kim et al. 2006). Recent investigations 
revealed a novel role for BMP7 in mediating the commitment of progenitors to the brown 
fat lineage (Tseng, Kokkotou et al. 2008). Different from white fat tissue, brown fat 
tissue is characterized by smaller adipocytes filled with multi-locular lipid droplets and 
abundant mitochondria, which catabolize lipid in response to cold stimulation (Cannon 
and Nedergaard 2004).  
Kang and associates conducted a thorough study of the importance of BMPs in 
regulating osteoblastogenesis and adipogenesis of MSCs. BMP2, BMP4, BPM6, BMP7 
and BMP9 are all shown to effectively induce both processes when over-expressed in the 
C3H/10T1/2 line of MSCs (Kang, Song et al. 2009). BMPs-induced MSCs fate 
commitment to each of these lineages was shown to be mutually exclusive both in vitro 
and in vivo (Kang, Song et al. 2009). Elucidation of the mechanisms underlying the 
BMP-regulated MSCs lineage divergence may lead to the development of preventative 
and therapeutic strategies for both obesity and osteoporosis. The role of BMP7 in 
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inducing brown fat differentiation should also be taken into consideration for combating 
co-development of obesity and osteoporosis.  
 
Insulin Like Growth Factor 1 (IGF1) Signaling in Osteoblastogenesis and 
Adipogenesis 
 IGF1 was originally characterized as an insulin-like soluble growth factor that is 
primarily expressed in the liver, but it is also found in most peripheral tissues (Yakar, 
Kim et al. 2005, Giustina, Mazziotti et al. 2008, Livingstone 2013).  IGF1 activates 
downstream cascades via IGF1 receptor (IGFIR) and IGF binding proteins (IGFBPs) and 
this signaling was shown to contribute to bone formation and remodeling (Peng, Xu et al. 
2003, Kawai and Rosen 2009, Govoni 2012). IGF1 induces osteoblastogenesis by 
activating mammalian target of rapamycin (mTOR) downstream pathways (Xian, Wu et 
al. 2012). Ablation of IGF1R in mice inhibited bone formation and led to an osteoporotic 
phenotype (Xian, Wu et al. 2012). A recent study showed that serum response factor 
(SRF) regulates bone formation through IGF1 expression and Runx2 transcription 
activity (Chen, Yuan et al. 2012).  
 Interestingly, IGF1 has also been found to promote adipogenesis by promoting the 
proliferation of adipogenic progenitors (Wabitsch, Hauner et al. 1995). IGF1 also 
regulates adipogenic differentiation through the phosphorylation of Akt1 (Protein Kinase 
B 1) and Akt2 (Protein Kinase B 2) (Peng, Xu et al. 2003). IGF1R has been demonstrated 
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to act downstream of advanced glycation end product (AGEs) signaling to promote 
adipogenesis in 3T3-L1 cells (Yang, Chen et al. 2013). 
 
Cell Shape Regulates MSCs Fate Commitment 
During the differentiation of MSCs, the cell morphology changes significantly in 
order to serve the specialized functions in different tissues (McBeath, Pirone et al. 2004). 
The adipocytes are round and lipid laden, a source of stored energy (Gregoire, Smas et al. 
1998), while the osteoblasts become spread and flattened for bone remodeling and 
mineral deposition (Sikavitsas, Temenoff et al. 2001). These differences of cellular 
morphologies are reported to be caused by the differences in the expression and 
organizations of cadherins, integrins and cytoskeleton proteins (Gumbiner 1996).  
While some reports state that differentiation of MSCs affects cell shape 
(Spiegelman and Farmer 1982), previous studies have also demonstrated that it is the 
changes in cell morphology that affect the differentiation of adipogenic 3T3-422A 
fibroblasts to mature adipocytes (Spiegelman and Farmer 1982, Spiegelman and Ginty 
1983). When pre-committed adipogenic 3T3-422A cells are allowed to attach to 
fibronectin-coated surfaces, the adipogenic differentiation is impaired as shown by 
inhibition of adipogenic gene expression and poor lipid droplet formation. These effects 
are rescued by disturbing the actin cytoskeleton organization (Spiegelman and Ginty 
1983). In contrast, an increase in cell spreading has been found to enhance 
20 
 
osteoblastogenesis with increased osteocalcin and osteopontin expression (Carvalho, 
Schaffer et al. 1998, Thomas, Collier et al. 2002). 
The role of cell morphological changes in regulating early commitment of MSCs 
has also been investigated by manipulating the degree of cell spreading and cell shape.  
McBeath used a micro-patterning technique to produce adhesive surfaces with different 
surface areas to manipulate the spreading of single human bone marrow MSCs (hMSCs) 
(McBeath, Pirone et al. 2004). HMSCs preferentially differentiate into adipocytes versus 
osteoblasts when attached to smaller fibronectin islands segregated by non-adhesive 
materials when given both adipogenic and osteoblastogenic growth factors. In contrast, 
the hMSCs on larger fibronectin islands differentiate into osteoblasts rather than 
adipocytes (McBeath, Pirone et al. 2004). This switch of lineage commitment is 
regulated by Ras homolog gene family, member A (RhoA) activity through the Rho-
associated protein kinase (ROCK) pathway. In fact, over-expression of RhoA in hMSCs 
enhances osteoblastogenesis, while over-expression of dominant-negative RhoA reverses 
this phenotype. The change in the activity of RhoA is sufficient to bypass the effects of 
differentiation inducers and dictate the commitment of MSCs to osteoblasts versus 
adipocytes (McBeath, Pirone et al. 2004).  
The transcriptional coactivator of Yes-associated protein (YAP), PDZ-binding 
motif (TAZ), has also been shown to regulate MSC commitment by inhibiting 
adipogenesis and enhancing osteogenesis (Hong, Hwang et al. 2005). Because the 
activity of TAZ-YAP signaling is closely associated with actin cytoskeleton 
polymerization (Kanai, Marignani et al. 2000), there may be a potential indirect 
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interaction between MRTFA (Myocardin-Related Transcription Factor A) –SRF (Serum 
Response Factor) and TAZ-YAP through actin dynamics in the regulation of MSCs fate 
commitment (Mendez and Janmey 2012). In summary, cell shape and cytoskeleton 
signaling regulate the early commitment of MSCs but the molecular mechanisms of these 
regulations remain to be elucidated.  
 
Rho ROCK Signaling Pathway 
The Rho family of GTPases are central regulators of cell motility functions such 
as cell migration, adhesion, spreading and polarization. This family includes Rho, Ras-
related C3 botulinum toxin substrate (Rac) and cell division control protein 42 homolog 
(Cdc42) subfamilies, (Jaffe and Hall 2005). They regulate the polymerization dynamics 
of G-actin (globular actin) and F-actin (filamentous actin) via several downstream 
effectors (Pollard 2007, Le Clainche and Carlier 2008). Rho GTPases promote actin 
polymerization through two mechanisms. Rac and Cdc42 can activate actin-related 
protein 2/3 (Arp2/3) through Wiskott-Aldrich syndrome protein (WASP) family 
members to initiate new branched actin filament formation (Ho, Rohatgi et al. 2004, 
Millard, Sharp et al. 2004). The other mechanism is mediated by Rho to activate formin 
family members, thereby increasing linear polymerization of actin filaments by adding 
monomers to the barbed ends (Zigmond 2004).  
Extracellular stimuli activate Rho GTPases through Rho guanine nucleotide 
exchange factors (GEFs) (Jaffe and Hall 2005). Rho GTPases are activated by the 
exchange of GDP for GTP, which leads to conformational changes in inactive 
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downstream effectors (Schmidt and Hall 2002).  Well-characterized downstream 
effectors of Rho GTPase include serine/threonine kinases and tyrosine kinases (Jaffe and 
Hall 2005).  
Activation of Rho GTPases promotes polymerization of G-actin into F-actin 
filaments mainly through ROCK and formins (Zigmond 2004). When cytoplasmic G-
actin levels decrease, myocardin-related transcription factors (MRTFs) are released from 
their association with G-actin for translocation into the nucleus. MRTFs bind and co-
activate SRF, thereby inducing cytoskeletal gene expression (Sotiropoulos, Gineitis et al. 
1999, Schratt, Philippar et al. 2002, Posern and Treisman 2006). These target genes are 
characterized as SRF class II target genes, including actin itself as well as several actin-
binding proteins which can regulate actin dynamics and cell motility (Norman, Runswick 
et al. 1988, Miralles, Posern et al. 2003). These newly synthesized proteins then elevate 
the cytoplasmic G-actin levels thereby providing a negative feedback loop by retaining 
MRTFs in the cytoplasm where it binds to G-actin (Vartiainen, Guettler et al. 2007). This 
regulatory circuit consisting of RhoA-ROCK-actin-MRTF-SRF is essential for the actin 
polymerization based cell motility functions (Olson and Nordheim 2010).  
 
Serum Response Factor (SRF) 
SRF is ubiquitously expressed in many cell types and it’s encoded by a single 
gene (Treisman 1986, Norman, Runswick et al. 1988). As a member of MADS-box (a 
conserved sequence motif found in MADS-box family genes) family, SRF is highly 
conserved from yeast to humans (Norman, Runswick et al. 1988, Shore and Sharrocks 
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1995). Homodimers of SRF regulate gene expression by specifically binding to CC (A/T) 
6GG cis elements, identified as CArG-boxes (Treisman 1986, Norman, Runswick et al. 
1988, Sun, Chen et al. 2006).   
Although the basal transcriptional activity of SRF is relatively low in cells, the 
binding and interaction with over 60 co-activators strongly potentiates target gene 
activation (Miano 2003, Benson, Zhou et al. 2011).  These co-activators can be 
categorized into two classes according to the functions of their target genes: Ternary 
complex factor (TCF) co-activators (Shaw, Schroter et al. 1989) and the myocardin 
family co-activators (Chang, Rickers-Haunerland et al. 2001, Wang, Chang et al. 2001). 
These two classes of co-factors bind to SRF and potently co-activate approximately 300 
target genes (Gineitis and Treisman 2001). 
mitogen activated protein (MAP) kinase phosphorylation activates members of 
the TCF family (Treisman 1986) E26 transformation-specific (Ets) type co-activators, 
including ETS-domain protein-1 (Elk-1), SRF accessory protein 1 (SAP1) and SRF 
accessory protein 2 (SAP2) (Hipskind, Rao et al. 1991, Dalton and Treisman 1992). 
These co-activators bind to SRF and strongly activate the immediate early genes 
including c-fos when induced with serum stimulation (Shaw, Schroter et al. 1989, 
Janknecht, Ernst et al. 1993).  The second type of co-activators is the myocardin family, 
myocardin and MRTFs. Myocardin is mostly expressed in smooth muscle and cardiac 
tissue (Wang, Chang et al. 2001, Wang, Wang et al. 2003, Creemers, Sutherland et al. 
2006), while MRTFA and MRTFB are more universally expressed (Ma, Morris et al. 
2001, Wang, Li et al. 2002). These co-activators have been shown to strongly potentiate 
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SRF-induced transcriptional activation of multiple smooth muscle and contractile genes 
in vivo and in vitro (Wang, Li et al. 2002, Du, Ip et al. 2003, Li, Wang et al. 2003, Small, 
Warkman et al. 2005).  In addition, the Nkx2-5 family of homeodomain proteins and the 
GATA family of zinc finger transcription factors positively regulate SRF transcription 
activity as co-factors (Chen and Schwartz 1996, Belaguli, Sepulveda et al. 2000, 
Sepulveda, Vlahopoulos et al. 2002). How these different co-activators work together to 
orchestrate SRF transcription activity during complex differentiation and development 
processes remains to be elucidated (Posern and Treisman 2006).  
The functions of SRF have been studied extensively in different model organisms 
and different organs in mice (Miano, Long et al. 2007). The SRF global deletion mice are 
not viable due to impaired gastrulation and defects in embryonic tissue layer migration 
before organogenesis even initiates (Arsenian, Weinhold et al. 1998). Deletion of SRF 
conditionally in mice has demonstrated essential functions of SRF in almost all organs 
(Miano 2010). For example, deletion of SRF in embryonic hearts inhibits cardiogenesis 
by reducing the transcription of cardiogenic genes (Niu, Yu et al. 2005).  Mosaic 
inactivation of SRF specifically in cardiac myocytes leads to significant inhibition of 
smooth muscle protein and contractile protein expression resulting in focal lesions and 
heart failure in mice (Parlakian, Charvet et al. 2005, Gary-Bobo, Parlakian et al. 2008). 
Deletion of SRF in skeletal muscle leads to marked decrease in muscle mass and 
disrupted sarcomeres (Charvet, Houbron et al. 2006). Tissue specific deletion of SRF in 
hepatocytes causes an abnormality in liver regeneration following partial hepatectomy, 
although the livers of SRF deletion mice are normal at birth (Latasa, Couton et al. 2007, 
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Sun, Battle et al. 2009). SRF deletion in neurons results in compromised neuronal 
migration due to disrupted actin cytoskeleton (Alberti, Krause et al. 2005, Knoll, Kretz et 
al. 2006). In vivo and in vitro results suggest an essential role for SRF in T-cell 
maturation and megakaryocytes functions as well (Fleige, Alberti et al. 2007, Halene, 
Gao et al. 2010). The functions of SRF in these tissues are mostly associated with the 
regulation of cell motility and contractility by regulating the actin cytoskeleton dynamics 
(Miano 2010).   
A previous study identified SRF as a positive regulator of bone mass maintenance 
(Chen, Yuan et al. 2012). The tissue specific deletion of SRF in mice leads to a 
significant decrease in bone mineral density and compromised bone formation. SRF is 
regulating skeletal homeostasis via IGF-1 expression and RUNX2 trans-activation 
activity (Chen, Yuan et al. 2012). Whether MRTFA is also involved in SRF regulated 
bone formation is still not determined.  On the other hand, by transducing 3T3-L1 cells 
with shRNA, SRF was shown to be a negative regulator for adipogenesis. Knocking 
down SRF enhances lipid droplet formation and adipogenic gene expression (Mikkelsen, 
Xu et al. 2010).  
In summary, SRF is an essential transcription factor that is potently co-activated 
by two classes of co-factors to activate the downstream immediate response genes or 
smooth muscle contractile genes (Figure 3). Previous evidence identified SRF as a 
positive regulator of bone formation but a negative regulator of adipogenesis, thus we 
propose that SRF important for the regulation of early MSC commitment downstream of 
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Rho-ROCK-actin and that MRTFs might be involved in this regulation as co-activators of 
SRF. 
 
Figure 3. MRTFs and TCFs potentiate SRF transcriptional activity in response to 
different signaling pathways. 
RhoA promotes actin polymerization through ROCK and formin, while Rac and 
Cdc42 achieve the same effect via WASP-Arp2/3 pathway. The polymerization of G-
actin liberates G-actin bound MRTFs which translocate into the nucleus and co-activate 
SRF target genes such as actin itself and actin binding proteins (ABPs) to regulate actin 
dynamics. On the other hand, upon activation by the Ras-Raf-MEK-Erk pathway, TCF 
complexes bind to SRF to co-activate immediate response genes such as c-fos.   
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Myocardin-related Transcription Factors (MRTFs) 
MRTFs belong to the myocardin family that includes myocardin, MRTFA and 
MRTFB (Wang, Li et al. 2002, Olson and Nordheim 2010). While the expression of 
myocardin is primarily in cardiac myocytes and smooth muscle cells (Wang, Chang et al. 
2001, Du, Ip et al. 2003), MRTFA and MRTFB are more widely expressed in different 
cell types (Wang, Li et al. 2002). MRTFA gene expression has been observed in 
embryonic stem cells and fibroblasts and it is highly abundant in MSCs, muscle cells and 
epithelial cells during embryogenesis. MRTFA has also been demonstrated to co-express 
with myocardin in human heart (Wang, Li et al. 2002, Du, Chen et al. 2004). MRTFB is 
enriched in the epithelial cells of the kidney, lung and testis during embryogenesis (Wang, 
Li et al. 2002).  
There is about 35% similarity for the amino acid sequences of the three family 
members, with several common conserved domains (Wang, Li et al. 2002). The most 
conserved domain is the RPxxxEL (RPEL) motif-containing domain in the N-terminus of 
the proteins. RPEL domains have been shown to regulate the interaction between MRTFs 
and G-actin monomers (Miralles, Posern et al. 2003, Posern, Miralles et al. 2004, 
Guettler, Vartiainen et al. 2008, Mouilleron, Guettler et al. 2008). The divergence of the 
sequence in the RPEL domain of myocardin abolishes its ability to bind with G-actin. As 
a result, the cellular localization of myocardin is not regulated by G-actin levels. In fact, 
myocardin is only present in the nucleus without nucleus-cytoplasm shuttling (Pipes, 
Creemers et al. 2006). Nevertheless, the activity of myocardin can be regulated indirectly 
by actin polymerization through heterodimerization with MRTFs through a conserved 
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leucine zipper domain (Wang, Wang et al. 2003). The B1 domain (a conserved domain 
found in the sequences of myocardin family members), located in between a basic 
domain and a glutamine-rich domain, is responsible for binding to SRF (Wang, Chang et 
al. 2001).  SAF-A/B, Acinus, and PIAS (SAP) domain is also a conserved region in 
myocardin and MRTFs that promote the induction of SRF target gene expression 
(Aravind and Koonin 2000, Wang, Chang et al. 2001). The transcription activation 
domain (TAD) in the C-terminus of these proteins is essential for the co-activation 
activity (Wang, Li et al. 2002). The dominant negative variants of MRTFs and SRF used 
in previous studies are truncated variants without the TAD domain (Chang, Wei et al. 
2003, Luchsinger, Patenaude et al. 2011).  
Myocardin and MRTFs are shown to be essential for development of various 
tissues by genetic studies using myocardin and MRTFs knockout mice (Oh, Richardson 
et al. 2005, Li, Chang et al. 2006, Sun, Boyd et al. 2006, Huang, Cheng et al. 2008, 
Huang, Min Lu et al. 2009). Previous studies conducted by Huang and coworkers showed 
the importance of myocardin in regulating the transcription of cell contractility genes in 
both cardiomyocytes and smooth muscle cells (Huang, Cheng et al. 2008, Huang, Min Lu 
et al. 2009). MRTFB deletion in mice results in embryonic death due to severe defects in 
cardiac neuronal crest development (Oh, Richardson et al. 2005).  The MRTFA null mice 
are viable, fertile and appear normal compared to the WT mice. However, the female 
MRTFA KO mice fail to nurse their pups normally due to an inability to produce milk, 
which is caused by defects in the mammary myoepithelial cell development and 
premature apoptosis in these cells (Li, Chang et al. 2006, Sun, Boyd et al. 2006).    
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The nucleus-cytoplasm shuttling of MRTFs is an essential component of the 
regulation the MRTF transcriptional activation functions. Recent studies showed that 
MRTFA is a negative regulator of adipogenesis via regulation of actin cytoskeleton 
dynamics (Nobusue, Onishi et al. 2014, McDonald, Li et al. 2015). MRTFA may play a 
similar role in the early lineage commitment of the bone marrow MSCs to osteoblasts 
versus adipocytes.  
 
Summary 
 Osteoporosis is a pressing public health issue consequent to the loss of bone mass 
and deterioration of bone micro-structure. Bone marrow adiposity often develops 
simultaneously with osteoporosis due to inappropriate MSCs fate switching to adipose 
versus osteoblastic lineage. Understanding the underlying mechanisms of early MSCs 
fate commitment may lead to the identification of potential drug targets for both obesity 
and osteoporosis.  
Cell shape has been shown to regulate the commitment of MSCs through Rho-
ROCK signaling pathway (McBeath, Pirone et al. 2004).  In this study, we investigated 
whether the actin-MRTFA-SRF circuit acts downstream of the Rho-ROCK pathway to 
promote osteoblastogenesis and inhibit adipogenesis. By evaluating the phenotypes of 
MRTFA KO (MRTFA KO) mice, we investigated the role of MRTFA in bone formation. 
Furthermore, we used bone marrow derived MSCs from these mice to study whether 
MRTFA regulates the early commitment of MSCs. Finally, to further demonstrate the 
role of MRTFA-actin-SRF in MSCs fate switch, we investigated how adipogenesis and 
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osteoblastogenesis are affected in C3H/10T1/2 MSC lines that stably over-express 
MRTFA, SRF and their dominant negative variants.   
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MATERIALS AND METHODS 
Materials 
Dulbecco’s Modified Eagle’s Medium (DMEM) with 4.5 g/L glucose (Mediatech, 
Inc; Herndon, VA) was supplemented with 10% fetal bovine serum (Life Technologies, 
Grand Island, NY) and 1% penicillin/streptomycin (Mediatch, Inc; Manassas, VA). 
Minimum Essential Medium, Alpha 1X (α-MEM) with Earle’s salts, ribonucleosides, 
deoxyribonucleosides & L-glutamine was obtained from Mediatch, Inc. (Manassas, VA) 
and was also supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin 
as mentioned above. Dexamethasone, indomethacin, 3-isobutyl-methylxanthine, T3, 2-
Phospho-L-ascorbic acid trisodium salt and Alizarin Red S powder was obtained from 
Sigma-Aldrich (St. Louis, MO). β-Glycerophosphate, Disodium Salt, Pentahydrate were 
purchased from Santa Cruz Biotechnology (Dallas, TX). Recombinant insulin and TRIzol 
reagents were purchased from Life Technologies (Carlsbad, CA). Recombinant BMP7 
and TGFβ1 proteins were purchased from R&D Technologies (North Kingstown, RI). 
Halt protease inhibitor cocktail was purchased from Pierce (Rockford, IL).  CCG1423 
compound was purchased from Cayman Chemical Company (Ann Arbor, MI). 
C3H10T1/2 cells were purchased from the American Type Culture Collection (Manassas, 
VA). 
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Animals 
All the studies and experimental procedures were approved and supervised by the 
Institutional Animal Care and Use Committee of Boston University. The breeding and 
experimental procedures were set up properly according to the Guidelines for Care and 
Use of Laboratory Animals by the National Institute of Health. The MRTFA+/– and WT 
mice (mixed C57BL/6J 129 genetic background generated by Dr. Barbara Smith’s 
Laboratory, Boston University School of Medicine) were originally generated by Dr. Eric 
Olson, UT Southwestern Medical Center (Li, Chang et al. 2006) and were given to us as 
a kind gift. All mice were kept in a 12 hour light/dark cycle at 23°C with free access to 
normal chow in the Boston University Laboratory Animal Science Center (McDonald, Li 
et al. 2015). Age-, strain- and sex- matched WT mice were used in all experiments as 
controls for the MRTFA KO mice.  
For the micro-computed tomography (Micro-CT) studies, the femur samples were 
isolated from adult males between the ages of 15-17 weeks old and adult females 
between the ages of 23-24 weeks. Some of these femur samples were then decalcified for 
histological studies. All the bone marrow-derived MSCs used for ex vivo studies, mRNA 
and protein samples of total femurs were isolated from matched male and female mice 
between the ages of 8 to 12 weeks old.  
 For the diet studies, 4-6 week old male WT and MRTFA KO mice were fed with 
a diet with 10% kcal% fat [low fat diet (LFD), Research Diets Inc., D12450B] or a diet 
with 60% kcal% fat [high fat diet (HFD), Research Diets Inc., D12492] for 6 weeks. The 
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femurs of these mice were then harvested for Micro-CT studies. Serum samples were also 
collected from these mice by placing the blood drawn from the hearts into anti-coagulate 
blood collection tubes. These blood samples were placed on ice for 30 minutes and then 
spun for 90 seconds at 1,500 x g to separate the serum for ELISA assays.  
 
 
Quantitative Micro-Computed Tomography (Micro-CT) Analysis 
Mice femurs were harvested, fixed in 4% formaldehyde for 5 days and then 
placed in PBS at 4°C for experiments. Scans were performed using a Scanco micro-CT 
40 system (Scanco Medical, Basserdorf, Switzerland) located in the Orthopedic and 
Developmental Biomechanics Laboratory at Boston University (assisted by Dr. Elise 
Morgan, Zackery Webster and Gabriel McDonald). These scans were performed using 12 
micron voxel size resolution with 200 ms integration time, under conditions of 55 E 
(KVp) and 145 I (μA). Transverse images scanned by the micro-CT were then traced 
manually with a computer program and stacked to render a 3D image of the cortical and 
trabecular femurs from WT or MRTFA KO mice (Bouxsein, Boyd et al. 2010).  
  For trabecular bone analysis, the metaphysis was identified by starting the scans 4 
mm from the distal end of the femurs and taking 130 slices (at 12 m per slice) distally 
for a total scanned region of 1.6 mm. The trabecular bone was quantitatively analyzed 
using a semi-automated segmentation protocol with a fixed threshold of 225 (for male 
mice) or 188 (for female mice). The total volume, bone volume, trabecular thickness, 
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trabecular number, connectivity density, trabecular separation, average bone mineral 
density and total tissue mineral density were calculated according to the standard 
algorithms provided by the system manufacturer.  
 For cortical bone analysis, the mid-diaphyseal region was located half way along 
the length of the bone and a total of 50 slices (12 µm/slice) within a region of 0.6mm (25 
slices above and below the mid-point) were scanned. The cortical bone was separated for 
quantitative analysis using a semi-automated segmentation protocol with a fixed 
threshold of 250 (for male mice) or 220 (for female mice). The total bone volume, 
cortical bone volume, cortical thickness and average bone mineral density were 
calculated according to the standard algorithms provided by the system manufacturer.  
3D images of both the trabecular and cortical bone of the mentioned mice were then 
generated for comparison of bone morphology between WT and MRTFA KO mice.  
 
DNA Isolation and Genotyping by PCR 
Mouse tails were cut (approximately 2mm) and digested in 300 l of 50 mM 
NaOH at 95°C for 90 minutes to 120 minutes (vortex vigorously every 20-30 minutes).  
30l of 1M Tris (PH=8) and 250 l of Phenol: Chloroform were added followed by 
vigorous vortexing. The samples were centrifuged at 15000 x g at 4°C for 5 minutes and 
the supernatant was collected. To the supernatant, 300 l of isopropanol and 30 l 
sodium acetate (PH 5.2) were added followed by vigorous vortexing. These samples were 
then centrifuged at maximum speed for 20 minutes.  The supernatant was discarded and 
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the precipitation was washed with 500 l of cold 70% ethanol (spin at maximum speed 
for 5 minutes). After the second centrifugation, the supernatant was discanted and the 
pellet was left in the chemical hood for air-drying. The genome DNA was then re-
suspended in 250 l of Tris-low-EDTA buffer and the DNA concentration was measured 
by spectrophotometry.           
To screen for MRTFA WT and KO alleles, primers were designed to amplify the 
WT fragment (600bp) and KO fragment (350bp). For PCR, 120ng of DNA was added to 
10 l of GoTaq Green Master Mix (Promega), 4 l H2O, 2 l of 1 M GT5 sense primer, 
1 l of 1 uM GT6 anti-sense primer and 1 l anti-sense primer LacZ3-QB for 2 minutes 
at 94°C and then followed by 30 cycles of 20 seconds at 94°C, 30 seconds at 57°C and 45 
seconds at 72°C. Finally, after 1 minute of incubation at 72°C, WT allele fragment of 
about 600 nucleotides and KO allele fragment of about 350 nucleotides were generated 
and then detected by electrophoresis on a 1% agarose gel to determine the genotypes of 
the mice.  
 
Histology 
              Mice femurs and tibiae were dissected, fixed in 4% formaldehyde for 5 days and 
then decalcified in 14% w/v EDTA dissolved in water for another 5 days. These samples 
were embedded in paraffin and sectioned (5 um section thickness) by Boston University’s 
Experimental Pathology Laboratory Services Core (Cheryl Spencer) (Carroll, Wigner et 
al. 2012). Sections of the femurs and tibiae were then de-paraffinized, rehydrated and 
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stained with Hematoxylin & Eosin to visualize the bone mass and marrow contents. 
Bright field images were obtained by light microscope. 
 
ELISA Assays 
The Enzyme-Linked Immunosorbent Assay (ELISA) Kit (SEA957Mu 96 tests) 
for Procollagen I N-Terminal Propeptide (PINP) for mouse serum was purchased from 
Cloud-Clone Corp. (Houston, TX). The assays were performed according to the 
manufacturer’s instructional manual. Both the freshly diluted standards and diluted serum 
samples were incubated in the provided ELSA kit wells for 2 hours at 37°C. Liquid was 
removed without washing and 100 l biotinylated detection antibody were added to each 
well for 1 hour incubation at 37°C. After adequate washing, 100 l HRP (Horseradish 
Peroxidase) conjugate were added for 30 minutes at 37°C. Following adequate washing, 
90 l of substrate solution were added to the wells for 15 -25 minutes at 37°C and then 
50 l of stop solution was added for optical density (OD) values reading using a micro-
plate reader set to 450 nm. Using the best fitting curved created with the values generated 
from the diluted standards, the concentrations of PINP in each sample were calculated. 
The ELISA assay (E-EL-M0366 96 tests) for the Mouse Cross Linked C-telopeptide of 
Type I Collage (CTX-1) (Purchased from Elabscience, Wuhan, P.R.C.) was also 
performed according similar instructions provided by the manufactures.  
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Cell Culture and Treatments 
C3H/10T1/2 cells were obtained from the American Type Culture Collection and 
maintained at 37°C and 5% CO2 in a cell culture incubator.  For adipogenic induction, at 
confluence, cells were induced to differentiate in DMEM supplemented with 10% FBS, 5 
μM dexamethasone, 0.5 mM isobutylmethylxanthine (IBMX), 860 nM insulin, 1 nM 3, 3, 
5-triiodo-L-thyronine (T3), and 125 μM indomethacin. 48 hours post induction; the cells 
were maintained in medium containing 10% FBS, 860 nM insulin, and 1 nM T3 for 
another 6 days (McDonald, Li et al. 2015). For osteoblastogenic induction, after the cells 
reached confluence, they were treated with DMEM supplemented with 10%FBS, 5 nM 
dexamethasone, 50µM L-ascorbic acid and 8 mM β-glycerophosphate, disodium salt for 
21 days (Carroll, Wigner et al. 2012) (Figure 4).  
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Figure 4. A scheme for adipogenic and osteoblastogenic differentiation in 
C3H/10T1/2 cells. 
For adipogenic differentiation, the cells were induced at confluence with 5 μM 
dexamethasone, 0.5 mM IBMX, 860 nM insulin, 1 nM 3, 3, 5-triiodo-L-thyronine (T3), 
and 125 μM indomethacin. 48 hours post induction; the cells were kept in medium 
containing 860 nM insulin, and 1 nM T3 for another 6 days. BMP4 or BMP7 were added 
to the cells three days prior to adipogenic induction for activating brown fat genes. For 
osteoblastogenic induction, after the cells reached confluence, they were induced with 5 
nM dexamethasone, 50µM L-ascorbic acid and 8 mM β-glycerophosphate, disodium salt 
for 21 days (Caplan and Bruder 2001). 
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Plasmids and Viral Transduction 
MRTFA, DN-MRTFA, SRF and DN-SRF cDNAs (Chang, Wei et al. 2003, 
Luchsinger, Patenaude et al. 2011) were kind gifts from Dr. Matthew Layne (Boston 
University School of Medicine). The fragments of these cDNAs were enzymatically 
digested out of the original plasmids at Hind III sites and then sub-cloned into the 
pMSCV retroviral vector (Clontech) by ligation at the Hind III sites. MRTFA, DN-
MRTFA cDNA were tagged with FLAG-tag at the C-Terminus. FLAG tags were also 
added via PCR to the C-Terminus of SRF and DN-SRF cDNA (Figure 5).  
EcoPack (Clontech) packaging cells were used for retrovirus production. These 
cells were transfected at 70% confluence by using Lipofectamine LTX and Plus Reagent 
(Invitrogen) and 8 μg of the respective pMSCV vectors. The viral supernatant was 
harvested and filtered with 0.45um filters 48 hours after the transfection.  50% 
confluence C3H/10T1/2 cells were incubated for 12 hours with the viral supernatant 
containing 10 μg/mL polybrene. These cells were then selected with 350 μg/mL 
hygromycin over 3-4 passages to establish stable over-expression cell lines of the 
mentioned proteins.  
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Figure 5. MRTFA, DN-MRTFA, SRF and DN-SRF over-expressing plasmids.  
MRTFA, SRF and their truncated variants without the transcription activation 
domain (TAD) in the C-terminus were sub-cloned in pMSCV retroviral vector (Clontech). 
Retro virus was produced to infect C3H/10T1/2 cells to establish stable over-expression 
cell lines. The DN-MRTFA has 630 amino acids, while DN-SRF has 266 amino acids 
(Olson and Nordheim 2010).  
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Isolation and Differentiation of Bone Marrow Mesenchymal Stem Cells (BM-MSCs) 
WT and MRTFA KO mice were euthanized and their femurs and tibiae were 
extracted without the soft tissues. The bone marrow cavity contents were flushed out with 
a 23G needle attached to a 10ml syringe containing αMEM growth media. The bone 
marrow contents were re-suspended and filtered using 100um cell strainers. The cells, 
which passed through the strainers, were counted and plated without being disturbed until 
day 4 of culture when half of the media was replaced. On day 6 of culture, for the 
osteoblastogenic induction, these cells were treated with  αMEM containing 10%FBS, 5 
nM dexamethasone, 50 µM L-ascorbic acid and 8 mM β-glycerophosphate, disodium salt 
for 21 days (Carroll, Wigner et al. 2012). For the adipogenic induction, the cells were 
treated with αMEM supplemented with 10% FBS, 5 μM dexamethasone, 0.5 mM 
isobutylmethylxanthine, 860 nM insulin, 1 nM 3, 3, 5-triiodo-L-thyronine (T3), and 125 
μM indomethacin. 48 hours post induction; the cells were maintained in medium 
containing 10% FBS, 860 nM insulin, and 1 nM T3 for another 6 days. For SRF 
inhibition experiments, 1 mM CCG1423 (Cayman Chemicals) was added to the cells for 
3 days prior to induction of adipogenic induction, while 1mM CCG1423 were 
supplemented in the osteoblastogenic induction media for 21 days.  
 
Quantitative Reverse Transcription-based Polymerase Chain Reaction (RT-PCR) 
Total RNA was isolated from C3H10T1/2 cells or tissues using TRIzol reagent 
(Life Technologies), chloroform was added to the TRIzol extracted samples followed 
with vigorous vortexing.  The milky mixture was then centrifuged at 14,000 X g for 15 
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minutes, after which the aqueous phase of the mixture was removed without disturbing 
the white protein layer. Isopropanol was then added to the aqueous phase followed by 
vigorous vortexing and then the mixture was placed at -20°C for 2 hours for RNA 
precipitation. After 10 minutes of centrifugation at 14,000 X g, the supernatant was 
discarded and the RNA pellets were left behind for air-drying in the chemical fume hood 
(McDonald, Li et al. 2015). The RNA pellets were then dissolved in 14-20 µl nuclease-
free water and quantified with a Nano Drop machine (Varelas Laboratory, BUSM) for 
RT-PCR reactions. 
             Mice femurs were dissected and the soft tissues were removed as much as 
possible. These femurs were snap-frozen in liquid nitrogen after sample collection and 
then pulverized in liquid nitrogen using a mortar and pestle. The pulverized samples were 
then placed in RNA extraction buffer RLT buffer (RNeasy Mini Kit) and the RNA 
extraction process was performed according to the manufacturer’s instruction.  
              Reverse Transcriptase (RT) reactions were performed using 2 μg RNA from 
either C3H10T1/2 cells or tissues and a high-capacity cDNA RT Kit (Applied 
Biosystems) according to the manufacturer’s instructions. RT random primers, RT buffer 
provided by the kit, high-capacity reverse transcriptase and dNTP were added to each RT 
reaction according to the suggested concentrations provided by the instructional manual. 
Diluted cDNA was used for Quantitative RT-PCR in 96-well plates performed 
with the Fermentas Maxima SYBR Grenn RT-PCR Master Mix (Fermentas Life 
Sciences) in the ABI Prism 7300 sequence detector. The PCR program used was 
consisted of with an initial denaturation step at 95 ͦC for ten minutes, followed with a 
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denaturation step for 15 seconds at 95 ͦC, a 20 second annealing step at 60 ͦC, and a 30 
second elongation step for 30 seconds for a total of 40 cycles. SYBR green fluorescence 
emissions were quantified at the end of each cycle for evaluating the mRNA levels. 
mRNA levels of genes were calculated by normalizing to the level of Gapdh. Primer 
sequences used for RT-PCR analysis are listed as follows: 
Acta-F: 5’-GTCCCAGACATCAGGGAGTAA-3’ 
Acta-R: 5’-TCGGATACTTCAGCGTCAGGA-3’ 
Adipoq-F: 5’-TGTTCCTCTTAATCCTGCCCA-3' 
Adipoq-R: 5’-CCAACCTGCACAAGTTCCCTT-3’  
Alpl-F: 5’- GCACCTGCCTTACCAACTCT-3’ 
Alpl -R: 5’-TGGAGTTTCAGGGCATTTTT-3’ 
Bglap-F: 5’-CTGACCTCACAGATGCCAAG-3’  
Bglap-R: 5’-GTAGCGCCGGAGTCTGTTC-3’ 
Cebpa-F: 5’-CAAGAACAGCAACGAGTACCG-3’  
Cebpa-R: 5’-GTCACTGGTCAACTCCAGCAC-3’  
Cidea-F: 5’-TGCTCTTCTGTATCGCCCAGT-3’ 
Cidea-R: 5’-GCCGTGTTAAGGAATCTGCTG-3’  
Col1a1-F: 5’-GCTCCTCTTAGGGGCCACT-3’  
Col1a1-R: 5’-CCACGTCTCACCATTGGGG-3’ 
Col3a1-F: 5’-CTGTAACATGGAAACTGGGGAAA-3’  
Col3a1-R: 5’-CCATAGCTGAACTGAAAACCACC-3’  
Cox7a1-F: 5’-GCTCTGGTCCGGTCTTTTAGC-3’ 
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Cox7a1-R: 5’-GTACTGGGAGGTCATTGTCGG-3’  
Elovl3-F: 5’-TTCTCACGCGGGTTAAAAATGG-3’  
Elovl3-R: 5’-GAGCAACAGATAGACGACCAC-3’  
Fabp3-F: 5’-AGTCACTGGTGACGCTGGACG-3’  
Fabp3-R: 5’-AGGCAGCATGGTGCTGAGCTG-3’  
Fabp4-F: 5’-AAGGTGAAGAGCATCATAACCCT-3’ 
Fabp4-R: 5’-TCACGCCTTTCATAACACATTCC-3’ 
Gapdh-F: 5’-AGGTCGGTGTGAACGGATTTG-3’  
Gapdh-R: 5’-TGTAGACCATGTAGTTGAGGTCA-3’  
Igf1-F: 5’- TGACATCCGCAACGACTATCA-3’ 
Igf1-R: 5’- CCAGTGCGTAGTTGTAGAAGAGT-3’ 
Igf1r-F: 5’- TGACATCCGCAACGACTATCA-3’ 
Igf1r-R: 5’- CCAGTGCGTAGTTGTAGAAGAGT-3’ 
Mrtfa-F: 5’- AGGACCGAGGACTATTTGAAACG-3’  
Mrtfa-R: 5’-CCACAATGATAGCCTCCTTCAG-3’ 
Mrtfb-F: 5’-ATGCCTTGAGGGAAGCAACC-3’  
Mrtfb-R: 5’-GCTCGCTCCAGGCTTTTTATC-3’ 
Plin-F: 5’-ATGTCAATGAACAAGGGCCCAACC-3’ 
Plin-R: 5’-TGGTGCTGTTGTAGGTCTTCTGGA-3’ 
Pparg-F: 5’-TCAGCTCTGTGGACCTCTCC-3’ 
Pparg-R: 5’-ACCCTTGCATCCTTCACAAG-3’ 
Runx2-F: 5’-CGAGACCAACCGAGTCATTT-3’ 
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Runx2-R: 5’-ACGCCATAGTCCCTCCTTTT-3’ 
Sp7-F: 5’-TTTCTCATTAACTCGTTGCCATCT-3’  
Sp7-R: 5’-CTTCGGGAAAACGGCAAATA-3’ 
Spp1-F: 5’- AAGGCGCATTACAGCAAACACTCA-3’ 
Spp1-R: 5’- CTCATCGGACTCCTGGCTCTTCAT-3’ 
Spock-F: 5’- ACCCCCGGCAATTTCATGG-3’ 
Spock-R: 5’- TGTCTTCCCAGCTCTTGATGTAA-3’ 
Srf-F: 5’-GGCCGCGTGAAGATCAAGAT-3’ 
Srf-R: 5’-CACATGGCCTGTCTCACTGG-3’ 
Ucp1-F: 5’-ACTGCCACACCTCCAGTCATT-3’ 
Ucp1-R: 5’-CTTTGCCTCACTCAGGATTGG-3’ 
 
Western Blot Analysis 
            Total cellular protein was extracted from primary bone marrow stem cells or 
C3H10T1/2 cells with RIPA protein extraction buffer containing 10% proteinase 
inhibitor (McDonald, Li et al. 2015). MRTFA KO and WT mice femurs were dissected, 
snap-frozen in liquid nitrogen after sample collection and then pulverized in liquid 
nitrogen using a mortar and pestle in 600ul RIPA protein extraction buffer (Carroll, 
Wigner et al. 2012).  
              The mentioned samples were then homogenized with sonication to break up the 
genome DNA. The lysates were vortexed and centrifuged at 14,000 X g for 10minutes 
after incubating on ice for 30 minutes. The supernatant was collected from these 
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centrifuged samples without disturbing the cells or tissue debris. After quantification of 
the supernatant using the BCA (bicinchoninic acid) Protein Assay Reagent kit (Pierce), 
all the protein samples were normalized in 5X reducing buffer containing 200mM Tris 
pH 6.8, 8% SDS, 0.4% bromophenol blue, 40% glycerol and 400 mM DTT.  The protein 
samples were subsequently fractionated by 10% -12% SDS-PAGE and transferred to 
PVDF (polyvinylidene difluoride) membranes purchased from BioRad at 120 mA voltage 
for overnight. PVDF membranes containing the protein samples were blocked with 5% 
non-fat milk powder dissolved in 1x PBST buffer and incubated with various primary 
antibodies specific to different proteins. Secondary antibodies (Sigma) conjugated with 
horseradish peroxidase and an ECL substrate kit (purchased from Denville) were used to 
develop the membranes for comparing the levels of target proteins (McDonald, Li et al. 
2015).  
              The primary antibodies against the following proteins were obtained from the 
indicated vendors: MRTFA, Osteopontin, C/EBPα, SRF (Santa Cruz, CA), adiponectin 
(Pierce, Rockford, IL) and cyclophilin A (Cyc A) (Millipore, Billerica, MA). Monoclonal 
antibodies against FABP4 (aP2), and polyclonal antibodies against Perilipin were 
obtained from Cell Signaling (Danvers, MA). Monoclonal antibodies against αSMA were 
obtained from Sigma-Aldrich (St. Louis, MO).  
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Alizarin Red S Staining 
  Bone marrow stromal derived MSCs were allowed to differentiate into mature 
osteoblasts for 21 days as described before. To assess mineralized nodules, the 
differentiated cells were washed with PBS, and then fixed with 10% formaldehyde at 
room temperature for 10 minutes. The 2% (w/v) Alizarin Red S staining solution was 
made by dissolving 2 grams of Alizarin Red S powder in 100ml H2O (adjust the pH to 
4.1-4.3 with ammonium hydroxide) and the solution was filtered with 0.45µm filters. 
Following the fixation, cells were washed with water and stained with 2% alizarin red 
solution at room temperature for 30 minutes. Following staining, cell layers were rinsed 
with deionized water until washes were clear (Carroll, Wigner et al. 2012).  Digital 
photographs of stained cells were then captured. 
 
Statistical Analysis 
Data are presented as mean values +/- standard error of means (SEM). Unpaired 
2-tail Student’s t-test was conducted to assess statistical significance and p ≤ 0.05 was 
considered significant.  
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RESULTS 
MRTFA KO Mice have Reduced Trabecular Bone Mass 
Introduction 
Osteoporosis is a skeletal disorder characterized by excessive bone loss and 
increased fragility fractures. And it often results in poor quality of life predominantly in 
the aging population (Raisz 2005). Several previous reports suggested that a possible 
mechanism for age-related osteoporosis is the inappropriate bone marrow MSC fate 
switch to adipocytes versus osteoblasts (Beresford, Bennett et al. 1992, Justesen, 
Stenderup et al. 2001). McBeath identified the RhoA-ROCK pathway as a crucial 
regulator for MSC fate commitment through regulation of cell morphology and spreading 
(McBeath, Pirone et al. 2004). As downstream effectors of RhoA-ROCK signaling, 
MRTFA and SRF potently activate the expression of actin and proteins regulating actin 
turnover and polymerization. Therefore, we hypothesize that the actin-MRTFA-SRF 
circuit is acting downstream of RhoA-ROCK to regulate the early commitment of MSCs.   
The original MRTFA KO mice were generated by Dr. Eric Olson’s laboratory 
where workers identified MRTFA as an essential regulator of mammary myoepithelial 
cell development and survival (Li, Chang et al. 2006). Dr. Barbara Smith’s laboratory 
also studied the role of MRTFA in regulation of collagen gene expression in 
myofibroblasts using the MRTFA KO mice. They discovered that MRTFA regulates 
collagen gene expression in pulmonary fibroblasts through a novel MRTFA Sp1 
interaction to enhance collagen expression independent of SRF (Luchsinger, Patenaude et 
al. 2011). We collaborated with Dr. Barbara Smith and Dr. Matthew Layne to further 
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characterize the phenotype of MRTFA KO mice. McDonald and Li from our group 
showed that knocking out MRTFA enhances the development of beige adipocytes in 
white adipose tissue. Moreover, the MRTFA KO mice are resistant to diet-induced 
insulin resistance and obesity (McDonald, Li et al. 2015).  
Because the importance of MRTFA in bone mass maintenance and bone 
formation has never been investigated before, we are the first to document the effects of 
MRTFA on bone morphometry. In this study, we compared body weight, femur and tibia 
length in MRTFA KO and WT mice. We also measured bone morphometric parameters 
in both cortical and trabecular bone using Micro-CT analysis. Cortical bone, also known 
as compact bone, forms the cortex of most of the bones. Trabecular bone is more porous 
and it often has more bone remodeling activity, therefore it is more severely affected in 
osteoporosis than cortical bone. 
We mainly focused on the pathological relevant bone morphometric parameters 
including bone volume fraction (BV/TV) in both cortical and trabecular bone, cortical 
thickness, estimated bone density and trabeculae parameters. The osteoblastogenic gene 
expression in femurs and the levels of serum markers for osteoblast and osteoclast 
activity were also measured in the MRTFA KO and WT mice.  
Recent studies demonstrate that obesity can lead to excessive bone loss by 
enhancing adipogenesis and inhibiting osteoblastogenesis in the bone marrow MSCs 
(Cao 2011). To investigate whether MRTFA deletion can potentiate bone loss under 
adipogenesis-inducing conditions, we analyzed the bone morphometric parameters of WT 
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and MRTFA KO mice fed with LFD or HFD, the latter causing adipose expansion, in 
part through hyperplasia.  
 
MRTFA KO Mice have Significantly Lower Whole Body Weight, Shorter Tibia and 
Femur Lengths than WT Controls. 
Dr. Matthew Layne’s laboratory first discovered that the MRTFA KO mice 
appear to be smaller than the WT mice. To confirm this finding and further explore 
whether this is due to the compromised skeletal development in the MRTFA KO mice, 
we measured whole body weight, femur and tibia length in both male and female WT and 
MRTFA KO mice.  The femurs and tibiae were dissected from 17 week old matched 
male WT and MRTFA KO mice and their lengths compared (Figures 6 and 7). Both the 
femurs and tibiae from MRTFA KO mice were significantly shorter than those from the 
WT mice (Figure 6 and 7). 
We then gathered one cohort of male mice (WT n=7, MRTFA KO n=7) and one 
cohort of female mice (WT n=7, MRTFA KO n=7) to measure their whole body weight 
and femur and tibia length for comparison. For the male mice (15-17 weeks old), 
MRTFA KO mice have significantly lower body weights averaging 29.9 grams as 
compared to the controls averaging 32.2 grams (Figure 7). The femurs and tibiae are also 
significantly shorter in the MRTFA KO male mice (Figure 7). The female mice (24 
weeks old) also showed similar phenotypes: the weights of WT mice averaged 27.1 
grams, while the MRTFA KO mice averaged 24.4 grams (Figure 8). The female MRTFA 
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KO mice also had significantly shorter femurs and tibiae when compared with the 
controls (Figure 8).  
From these observations, we speculate that the shorter femurs and tibiae in the 
MRTFA KO might be due to compromised osteoblast differentiation during skeletal 
development, although other mechanisms such as defects in chondrocyte differentiation 
or growth plate development should also be taken into consideration. Due to 
aforementioned defects in the female MRTFA KO mammary myoepithelial cells 
development, we only used MRTFA+/- female mice for breeding purpose and the selected 
WT and MRTFA KO mice for experiments were all nursed by the same MRTFA+/- 
mother.  
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Figure 6. MRTFA KO Mice have shorter femurs and tibiae as compared to the 
controls. 
Both femurs and tibiae were dissected from 17 week old matched male WT and 
MRTFA KO mice. The upper and lower orange line mark the beginning and end of the 
WT mouse femurs to show the differences in the lengths of WT and MRTFA KO mice.  
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Figure 7. Male MRTFA KO mice have lower body weight, shorter femur and tibia 
length as compared to the controls. 
 WT (n=7) and MRTFA KO (n=7) male mice (15-17 weeks old) were euthanized 
and then weighed. The femurs and tibiae of the mice were then dissected and the bone 
lengths were measured with a caliper. The data are expressed as mean +/- SEM (Standard 
Error of Deviation). Data were analyzed by Student’s t-test (** p≤0.01).  
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Figure 8. Female MRTFA KO mice have lower body weight, shorter femur and 
tibia length as compared to the controls. 
 The whole body weight, femur and tibia length for female WT (n=7) and MRTFA 
KO (n=7) mice were measured as described in Figure 7. The age of these mice range 
from 22 to 24 weeks old (* p≤0.05, ** p≤0.01).  
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MRTFA KO Mice Showed Marked Decrease in Bone Mass in the Trabecular Region 
of Femurs 
Micro-CT analysis has been used widely to evaluate trabecular and cortical bone 
structures in different animal models.  The Micro-CT scanning system offers a non-
destructive method to acquire high-resolution images of the micro-structures of ex vivo 
samples and it allows accurate quantification of the micro-architectural parameters of the 
samples as well (Bouxsein, Boyd et al. 2010).   
Micro-CT analysis was performed on the femur samples of 17 week old male and 
24 week old female WT and MRTFA KO mice. High-resolution 3D images of the bone 
microstructures were generated from the scans. Various trabecular and cortical bone 
morphometric parameters were quantified and compared. The overall morphology and 
size of the bone can be observed from the 3D images. Additionally, microstructural 
characteristics including cortical thickness and the morphology of trabeculae can be 
observed.  Trabeculae are the small rod or beam like bone structures in the trabecular 
bone. The size, morphology, density and degree of separation of trabeculae usually 
represent the quantity and quality of bone.  
The 3D images of the mid-diaphyseal region of cortical femur from male WT and 
MRTFA KO mice showed no obvious morphological differences (Figure 9A). The shape 
and size of the bones from WT and MRTFA KO were similar (Figure 9A).  However, the 
3D images of trabecular regions of proximal femurs showed a marked reduction in 
trabecular bone volume in the MRTFA KO mice as compared to WT controls (Figure 9B). 
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There was more spacing volume and less bone volume in the trabecular femurs from the 
MRTFA KO mice. The trabeculae appeared to be thinner in the MRTFA KO mice as 
well.    
Figure 9. Representative Micro-CT images of mid-diaphyseal cortical bone and 
trabecular bone of WT and MRTFA KO male mice. 
 Mouse femurs were harvested when the male mice were about 17 weeks old (WT 
n=7, MRTFA KO n=7). Representative three-dimensional images of mid-diaphyseal 
cortical regions (A) and trabecular regions (B) of femurs generated by Micro-CT analysis 
are shown. Transverse images scanned by the Micro-CT were traced manually with a 
computer program and stacked to render 3D images.  
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The 3D images of the scans generated from WT and MRTFA KO female mice 
showed similar trends as those observed in the male mice (Figure 10). Some of the 
MRTFA KO mouse cortical bone appeared to have thinner cortical thickness than in the 
WT bone. For the trabecular bone of the female mice, the MRTFA KO mice 
demonstrated a remarkable decrease in bone volume as shown in Figure 10B.  There was 
significantly less bone volume in the MRTFA KO mice with more trabecular spacing and 
much thinner trabeculae.  
The 3D images generated from male and female mice consistently showed that 
the MRTFA KO mice have significantly less bone volume and thinner trabeculae in the 
trabecular femurs. The female MRTFA KO mice seem to have a more severe 
osteoporotic phenotype than the male mice.  
Using software provided by the Scanco micro-CT 40 system, we quantified 
various bone morphometric parameters based on the 3D models of the area of interest in 
the above mentioned bone samples.  One of the pathological relevant cortical bone 
parameters we studied was cortical thickness, which is calculated as the average 
thickness of the femoral cortex (Bouxsein, Boyd et al. 2010). As shown in both Figure 11 
and Table 1, there was no statistically significant difference in cortical thickness between 
male WT and MRTFA KO mice, despite a non-significant trend of thinner cortical 
thickness in MRTFA KO mice (Table 1, Figure 11 p=0.09).  There was no significant 
difference between the bone volume fraction (BV/TV) of WT and MRTFA KO mice 
(Table 1, Figure 11). On the other hand, there was a marked decrease in total tissue 
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volume and bone volume (Table 1, Figure 11 lower panel), which is likely due to smaller 
overall bone size in MRTFA KO mice.   
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Figure 10. Representative Micro-CT images of mid-diaphyseal cortical bone and 
trabecular bone of WT and MRTFA KO female mice. 
 Representative 3D images of mid-diaphyseal cortical regions (A) and trabecular 
regions (B) of femurs generated by Micro-CT analysis are shown (as described in Figure 
9). Mice femurs were harvested when the female mice were about 24 weeks old (WT n=7, 
MRTFA KO n=7). The images of two pairs of WT and MRTFA KO female mice are 
shown to represent the remaining data.  
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Figure 11. MRTFA KO mice have smaller cortical bone but there is no significant 
difference in cortical thickness between male WT and MRTFA KO mice. 
The femur samples were harvested from 17 week old male mice (WT n=7, 
MRTFA KO n=7) and fixed in 10% formalin for 5 days before Micro-CT scanning. 
Software provided by the Scanco micro-CT 40 system was used to generate quantitative 
bone microstructural parameters shown in this figure. The cortical thickness, cortical 
bone volume fraction (BV/TV), total volume (TV) and bone volume (BV) of the mid-
shaft area of femurs are shown. The data is expressed as the mean values of the 7 mice in 
each group with standard error of deviation. (*p<0.05).   
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Figure 11  
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The same analytical approaches were used for the female mice samples to 
generate bone morphometric indices.  As shown in both Figure 12 upper panel and Table 
2, the cortical thickness of the female MRTFA KO mice was significantly thinner than 
the controls. However, there was no significant difference found between the BV/TV of 
WT and MRTFA KO female mice (Table 2, Figure 12 upper panel). Similar to the male 
mice, there was a marked decrease in both total tissue volume and bone volume in the 
mid-diaphyseal femurs of female MRTFA KO mice (Table 2, Figure 12 lower panel).  
The Micro-CT analysis of the trabecular region of male MRTFA KO mice 
showed that they had significantly less bone volume fraction (about 20% reduction when 
compared to the controls) (Figure 13C and Table 1). The BV of the MRTFA KO was 
lower than that of the WT controls (Figure 13B and Table 1), which might lead to lower 
bone volume fraction, given that there was no difference in the TV (Figure 13A and 
Table 1).   
The mean apparent mineral density of the total tissue was also significantly lower 
in the MRTFA KO mice (Figure 13E and Table 1), but no difference was found in mean 
density of the bone volume (Figure 13D and Table 1). The total bone tissue density was 
reduced in the MRTFA KO mice due to loss of bone mass since bone has a much higher 
density than the non-bone soft tissues.  In summary, the male MRTFA KO showed a 
small but significant reduction in trabecular bone mass when compared to the controls.  
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Figure 12. Female MRTFA KO have smaller cortical bone and thinner cortical 
thickness.  
As in figure 11, the femur samples were harvested from 24 week old female mice 
(WT n=7, MRTFA KO n=7) and scanned with Micro-CT.  The cortical thickness, 
cortical bone volume fraction (BV/TV), total volume (TV) and bone volume (BV) of the 
mid-shaft area of femurs are presented as mentioned in Figure 9 (**p<0.01).   
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Figure 12 
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Figure 13. Trabecular bone morphometric parameters comparison in male WT and 
MRTFA KO mice. 
The same samples were analyzed as described in Figure 11. The trabecular total 
volume (Trabecular TV) (A), trabecular bone volume (Trabecular BV) (B), trabecular 
bone volume fraction (BV/TV) (C), bone volume density (D) and total volume density (E) 
of the trabecular femurs are shown. The data are presented as described in Figure 9 
(*p<0.05).  
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Figure 13.  
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The Micro-CT analysis for the female mice demonstrated a more severe 
osteoporotic phenotype in the trabecular bone of the MRTFA KO mice. The trabecular 
bone volume fraction (BV/TV) was approximately 50% lower in MRTFA KO female 
mice as compared to the controls (Figure 14C and Table 2). This appeared to be due to 
the drastic reduction in the trabecular bone volume in the MRTFA KO mice as shown in 
Figure 14B and Table 2, although there were no significant difference in the total volume 
(Figure 14A and Table 2).   
Moreover, the mean density of the total tissue was lower in the MRTFA KO mice 
due to reduced bone mass fraction of the total tissue (Figure 14E and Table 2). However, 
there was no difference in the mineral density of the bone mass itself (Figure 14D and 
Table 2). Consistent with the results we discovered in the male mice, MRTFA KO mice 
displayed an osteoporotic phenotype in both genders and this phenotype was more 
prominent in the female mice.  
Based on the 3D calculations, the mean trabecular number (Tb. N.), mean 
trabecular thickness (Tb. Th.), mean trabecular separation (Tb. Sp.), mean connectivity 
density (Conn. D.) and structure model index (SMI) were determined for comparison. 
There was no significant difference in the male WT and MRTFA KO mice except for 
SMI (Table 1), which is an indicator of the shapes of the trabeculae. The values of SMI 
varied from 0 to 3: 0 represents perfectly parallel plates and 3 represents perfectly 
cylindrical rods. The mean SMI of WT mice was 1.54 and the MRTFA KO was 1.94, 
which indicates the trabeculae of the mice was more plate-like whereas those of the 
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MRTFA KO mice were more rod-like. This may suggest that the trabeculae in the 
MRTFA KO mice are thinner than the WT controls. However, the quantification of 
trabecular thickness did not show a significant difference between MRTFA KO and the 
controls.   
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Figure 14. Trabecular bone morphometric parameters: comparison of female WT 
and MRTFA KO mice. 
The same samples from Figure 12 were analyzed as described in Figure 11. The 
trabecular total volume (Trabecular TV) (A), trabecular bone volume (Trabecular BV) 
(B), trabecular bone volume fraction (BV/TV) (C), bone volume density (D) and total 
volume density (E) of the trabecular femurs are shown. The data are presented as 
described in Figure 9 (**p<0.01).  
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Figure 14.  
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On the other hand, the trabecular morphometric indices mentioned above were 
drastically different between female MRTFA KO mice and controls. The trabecular 
number (Tb. N.), which represents the measurement of mean number of trabeculae per 
unit length, was significantly lower in the female MRTFA KO mice (Figure 15A, Table 
2). However, no significant difference was found in the trabecular thickness (Tb. Th.) 
(mean thickness of trabeculae) and SMI (Figure 15B, E and Table 2) between MRTFA 
KO and control mice. The trabecular separation (Tb. Sp.), the mean distance between 
trabeculae, increased significantly in the female MRTFA KO mice (Figure 15C and 
Table 2). The connectivity density (Figure 15D and Table 2), a measure of the degree of 
connectivity of trabeculae, was much lower in the female MRTFA KO mice. The 
increase of trabecular separation and decrease of connectivity density collectively 
indicates less bone mass and more non-bone soft tissue in the trabecular bone of the 
MRTFA KO mice.   
Interestingly, several bone structure parameters such as bone volume fraction, 
trabecular number, trabecular separation, connectivity density and the mean tissue density 
were all significantly lower in the female WT and MRTFA KO mice as compared to the 
males (Table 3). The mean values of the female mice were approximately 50% to 90% 
less than that of the males (Table 3). With age and gender differences, both WT and 
MRTFA KO female mice were much more osteoporotic than the males. This may explain 
the severity of the osteoporotic phenotype in the female mice.  
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In conclusion, MRTFA KO mice had reduced bone mass in the trabecular femurs 
as compared to the WT controls and the female MRTFA KO mice have a more severe 
osteoporotic phenotype than the males.  
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Figure 15. Trabecular bone morphometric parameters representing bone mass were 
compared in female WT and MRTFA KO mice. 
The same samples from Figure 12 were analyzed as described in Figure 11. The 
trabecular number (Tb. N) (A), trabecular thickness (Tb. Th.) (B), trabecular separation 
(Tb. Sp.) (C), connectivity density (Conn. D.) (D) and trabecular structure model index 
(SMI) (E) of the trabecular femurs are shown. The data are presented as described in 
Figure 9 (*p<0.05, **p<0.01).  
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Figure 15.  
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Table 1.  MRTFA KO male mice have significant trabecular bone loss as compared 
to the WT mice.  
The femurs were obtained from male mice as described in Figure 11 and 13.  The 
data is expressed as the mean values ± standard error of deviation for each group 
(*p<0.05, **p<0.01). The cortical thickness, cortical BV/TV, TV and BV of cortical 
femurs are included. The trabecular bone morphometric parameters shown in this table 
are as follows: trabecular BV/TV, trabecular TV, trabecular BV, connectivity density, 
structure model index, trabecular number, trabecular thickness, trabecular density, mean 
density of total volume and mean density of bone volume.  
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Table 2. MRTFA KO female mice showed an osteoporotic phenotype as compared 
to the WT mice. 
The femurs were obtained from female mice as in Figure 10, 12 and 13. The data 
is shown as described in Table 1 (*p<0.05, **p<0.01). All the bone parameters shown are 
listed in Table 1.  
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Osteoblastogenic Gene Expression was reduced in MRTFA KO Mouse Femurs. 
To study whether the decreased bone mass in the MRTFA KO mice is caused by 
the inhibition of osteoblastogenesis, we compared the mRNA levels of osteoblastogenic 
genes in the femurs of MRTFA KO mice with the WT controls. The mRNA level of 
Mrtfa was consistently reduced in the MRTFA KO mice (Figure 16A) and the Mrtfa 
mRNA signal detected in the MRTFA KO mice might be from the incomplete fragments 
of Mrtfa mRNA.  
Expression of the osteoblastogenic transcription factor Runx2 mRNA was lower 
in the MRTFA KO mice compared to the WT mice (Figure 16A). mRNA levels of 
osteoblastogenic genes such as Alpl (Alkaline phosphatase), Spp1 (secreted 
phosphoprotein 1) and Bglap (bone gamma-glutamate protein) were also reduced in some 
of the MRTFA KO femurs (Figure 16A). Alpl levels are positively associated with bone 
formation, thus the decreased Alpl mRNA indicates inhibited osteoblastogenic activity 
(Komori, Yagi et al. 1997).  Osteopontin is an extracellular structural protein in bone that 
is very important for bone remodeling. Osteocalcin is a secretory protein that is important 
for mineralization and calcium homeostasis in bone (Komori, Yagi et al. 1997). The 
reduction of the mRNA levels of these genes suggests inhibited osteoblast differentiation 
in the MRTFA KO mouse femurs. The protein level of osteopontin was also significantly 
lower in the MRTFA KO mouse femurs (Figure 17B), which was consistent with the 
mRNA levels.   
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Insulin-like growth factor 1 (IGF1) is proven to be essential for bone formation 
during maintenance of bone homeostasis  in adult life (Peng, Xu et al. 2003).  A previous 
study showed that SRF regulates bone formation via the IGF1 and IGF1R signaling 
pathway (Chen, Yuan et al. 2012, Xian, Wu et al. 2012). We measured the mRNA levels 
of Igf1 and Igf1r in the MRTFA KO mice since MRTFA is a known co-activator of SRF 
target genes. Interestingly, mRNA levels of Igf1 and Igf1r in the MRTFA KO mouse 
femurs were also reduced, similar to the SRF knockout mice (Figure 16B). This might be 
partially responsible for the shorter femurs and tibiae and reduction of trabecular bone 
mass seen in the MRTFA KO mice. The trabecular region of the proximal femurs from 
WT and MRTFA KO mice was sectioned and stained with H&E. There is more non-bone 
soft tissue spacing (purple) and less mineralized bone mass (pink) in the MRTFA KO 
mice as shown in Figure 17A.   
The balance between bone formation and resorption is essential for proper bone 
remodeling. Based on the aforementioned results, we still cannot rule out that the 
osteoporotic phenotype in MRTFA KO mice is due to both inadequate osteoblastogenesis 
and excessive osteoclast activity. To further elucidate the mechanism of the bone loss in 
MRTFA KO mice, we measured the levels of the widely used clinical osteoporotic 
markers, PINP and CTX-1, in sera of WT and MRTFA KO mice.  PINP is a cleaving by-
product produced during Type I collagen synthesis and it is positively correlated with 
osteoblastogenesis activity. CTX-1 is the by-product of enzymatic cleavage of Type I 
collagen occurring during bone resorption by osteoclasts, thus serves as a marker for 
bone breakdown. PINP levels were significantly lower in MRTFA KO mouse serum as 
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compared to the controls in Figure 16A. Reduced PINP levels also indicate that 
osteoblastogenesis in other types of bone such as vertebrae are likely compromised in the 
MRTFA KO mice.  On the other hand, there is no significant difference in CTX-1 levels 
between WT and MRTFA KO mice, which suggests the osteoporotic phenotype in 
MRTFA KO mice is most likely due to the inhibition of osteoblastogenesis instead of 
excessive bone resorption by osteoclasts.   
Collectively, the Micro-CT analysis, osteoblastogenic gene mRNA levels and 
ELISA results showed that MRTFA KO mice have reduced bone mass in the trabecular 
femurs. The reduced bone mass in MRTFA KO mice is likely due to reduced 
osteoblastogenesis.   
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Figure 16. mRNA levels of select osteoblastogenic genes, IGF1 and IGF1R are lower 
in MRTFA KO femurs. 
The femurs of WT (n=3) and MRTFA KO mice (n=3) were dissected and pulverized in 
liquid nitrogen for mRNA extraction. Mrtfa, Runx2, Alpl, Spp1, Bglap (A), Igf1 and 
Igf1r levels (B) [WT (n=4) and MRTFA KO mice (n=4)] were probed with 
corresponding primers and the relative levels of these genes are presented. The fold 
change of these genes was normalized to Gapdh mRNA levels and the mean value of WT 
samples was set at 1. The dots of same colors represent matched WT and MRTFA KO 
mice samples. Alpl: alkaline phosphates, Igf1: insulin like growth factor 1, Igf1r: insulin 
like growth factor 1 receptor.  
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Figure 17. There is less bone mass in MRTFA KO femur in H&E staining and 
osteopontin protein is lower in MRTFA KO mice.  
Histological sections of proximal femur were stained with H&E to visualize the 
bone structures (A). The area with pink color and purple dots is mineralized bone mass, 
whereas the purple part is bone marrow cavity and contents (A). Femurs were obtained 
from WT and MRTFA KO mice for protein extraction in RIPA buffer. Western blots for 
osteopontin in 3 WT and 2 MRTFA KO mice are shown (B).  
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Figure 18. MRTFA KO mice have lower osteoblasts activity marker levels in the 
serum.  
 Blood samples were collected from the hearts of matched WT (n=6) and MRTFA 
KO (n=7) mice. ELISA assays were performed in diluted serum to measure the levels of 
procollagen I N-terminal propeptide (PINP) (A) and cross linked C-telopeptide of Type I 
collagen (CTX-1) (B). The data is expressed as described before (*p<0.05). 
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The Loss of MRTFA Potentiates Bone Mass Loss When Mice are Challenged with a 
High Fat Diet (HFD). 
Representative 3D images of the cortical and trabecular femurs from each group 
of mice (WT LFD, WT HFD, KO LFD and KO HFD) are shown in Figure 19. No 
significant difference was observed in the cortical thickness amongst the 4 groups in 
Figure 19A. On the other hand, the bone mass of MRTFA KO mice fed with either LFD 
or HFD appeared to be reduced compared to their WT counterparts (Figure 19B). There 
was less bone volume in the MRTFA KO mice and more non-bone soft-tissue spacing as 
shown in Figure 19B.  
The lengths of the femurs and tibiae of the 4 groups of mice were measured. 
There was no statistically significant difference between WT and MRTFA KO fed with 
LFD for either femur or tibia length (Figure 20A, B and Table 4). However, the MRTFA 
KO mice fed with a HFD for 6 weeks had significantly shorter femurs and tibiae (Figure 
20A, B and Table 4).   
Cortical thickness of HFD MRTFA KO mice was significantly thinner than the 
HFD controls, while there was no statistically significant difference between LFD WT 
and MRTFA KO mice (Figure 20C and Table 4). The trabecular BV/TV and connectivity 
density in HFD MRTFA KO mice were also reduced as compared to the HFD controls 
(Figure 20D, E and Table 4).  These differences were not seen between WT and MRTFA 
KO mice fed with LFD. In summary, the MRTFA KO mice were more susceptible to 
bone loss when challenged with a HFD.  
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Figure 19. Representative 3D images of mid-diaphyseal cortical bone and trabecular 
bone of WT and MRTFA KO male mice fed with either HFD or LFD. 
The femurs were harvested from 12 week old male mice (WT LFD n=6, MRTFA 
KO LFD n=8, WT HFD n=5, MRTFA KO HFD n=6). These mice were placed on 
different diets when they were 4-6 weeks old after weaning from MRTFA+/- mothers. WT 
and MRTFA KO mice were fed with a diet with 10% kcal% fat (low fat diet) or a diet 
with 60% kcal% fat (high fat diet) for 6 weeks. The representative 3D images of both 
cortical (A) and trabecular bone (B) of each group are shown to represent the remaining 
data. 
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Figure 20. MRTFA KO mice have an osteoporotic phenotype when challenged with 
HFD. 
The femurs were obtained from the mice as described in Figure 19. The femur 
length (A), tibia length (B), cortical thickness (C), trabecular BV/TV (D) and 
connectivity density (E) of the femurs are shown. The data is expressed as in Figure 9. 
Student’s T-tests were performed between WT LFD and MRTFA KO LFD, WT HFD 
and MRTFA KO HFD, respectively. (*p≤0.05). 
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Table 3. MRTFA KO developed an osteoporotic phenotype when challenged with 
HFD. 
The femurs were obtained from mice as in Figure 19 and 20.  The values shown 
in this table are the values of each mice group ± standard error. The bone morphometric 
parameters included are listed in Table 1.  
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Discussion 
 Osteoporosis is manifested by excessive loss of bone mass and increased 
tendency for pathological fractures. Previous studies showed osteoporotic bones have 
increased bone marrow adiposity in the trabecular region (Meunier, Aaron et al. 1971, 
Justesen, Stenderup et al. 2001, Rosen and Bouxsein 2006). Since adipocytes and 
osteoblasts differentiate from the common progenitors, the disruption of the fate switch 
between these two lineages will lead to decreased osteoblastogenesis and enhanced 
adipogenesis and osteoporosis (Rosen and Bouxsein 2006). The aim of thesis was to 
investigate whether or not the actin-MRTFA-SRF circuit acts downstream of RhoA-
ROCK signaling to dictate the MSC fate switch between osteoblasts and adipocytes.  
 Here, we studied the role of MRTFA in bone formation in vivo using a global 
MRTFA KO mouse model. The MRTFA KO mice had lower whole body weight, shorter 
femurs and tibiae in both genders. Although the lower whole body weight seen in the 
MRTFA KO phenotype might be due to the decreased fat mass discovered by others in 
our group, a reduction in bone size and bone mass might also be contributing to this 
phenotype (McDonald, Li et al. 2015).  
The defects of the bone lengths in MRTFA KO mice suggested that osteoblast 
development and function was impaired. Accordingly, we found that MRTFA KO mice 
had reduced osteoblastogenic gene mRNA levels. However, other mechanisms for the 
compromised longitudinal growth of the MRTFA KO bones such as defects in 
chondrogenesis and growth plate development should be explored in future studies. Since 
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Runx2 has been shown to regulate chondrocyte maturation and limb growth (Yoshida, 
Yamamoto et al. 2004), the inhibition of Runx2 in MRTFA KO mice (Figure 16A) might 
lead to impairment of chondrogenesis and contribute to the defects of longitudinal growth 
of limbs in the mice.  
 Micro-CT analysis performed on WT and MRTFA KO mice revealed an 
osteoporotic phenotype in the MRTFA KO mice. Female MRTFA KO had a thinner 
cortical thickness in the mid-diaphyseal area of the femurs, although the difference was 
not seen in the males. The MRTFA KO mice had smaller tissue volume and bone volume 
due to smaller overall bone sizes in both genders (Figure 11 and 12).  
 Both male and female MRTFA KO mice consistently exhibited a significant 
osteoporotic phenotype with decreased bone mass in trabecular femur. BV/TV was 
approximately 20% lower in the male MRTFA KO mice and approximately 50% lower 
in the females. The histological images of the trabecular femur validated this finding 
(Figure 17A). The osteoporotic phenotype was more striking in the female MRTFA KO 
mice as shown by the marked reduction of trabecular number, connectivity density and 
increase of trabecular separation. Reduced mRNA levels of osteoblastogenic genes and 
lower osteopontin protein expression were seen in MRTFA KO mice as well.  
Additionally, the serum levels of systemic osteoblasts activity marker PINP was 
decreased by more than 75% in the MRTFA KO mice. This indicates that the impairment 
of osteoblastogenesis might also be occurring in other bones, although we have not yet 
investigated the microstructures in other bones in the MRTFA KO mice. To investigate 
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whether excessive activation of osteoclasts contributed to the bone loss in the MRTFA 
KO mice, we measured the serum levels of osteoclast activity marker CTX-1. No 
significant differences were found in CTX-1 levels between WT and MRTFA KO mice, 
which suggests that excessive bone resorption is not the mechanism for the osteoporotic 
phenotype.  
 To study whether MRTFA is protective against osteoporosis in adipogenic-
inducing pathological conditions, we studied the changes of bone mass in WT and 
MRTFA KO mice fed with either LFD or HFD. The MRTFA KO mice exhibited 
decreased bone lengths and bone mass when challenged with HFD, but the difference 
between WT and MRTFA KO mice fed with LFD is not statistically significant despite a 
trend of decreased bone lengths in MRTFA KO mice. This finding suggests that ablation 
of MRTFA potentiated bone loss under adipogenic-inducing conditions such as HFD. To 
confirm whether there is more adipose tissue in the MRTFA KO mice bone marrow, 
histological examinations and measurements of adipogenic genes expression will be 
performed in future investigations.  
 There is a discrepancy in the Micro-CT results of older versus younger male mice. 
The decreased trabecular bone mass as seen in 17 week old MRTFA KO mice was not 
recapitulated in the 12 week old mice. When the MSC early fate commitment shifts 
towards adipogenesis over osteoblastogenesis as the mice age, the effect of MRTFA 
deletion might manifest itself more in bone remodeling. Also, MRTFB might compensate 
for the loss of MRTFA functionally to maintain a normal bone phenotype in the younger 
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MRTFA KO mice. We speculate MRTFA might play a more important role in the 
maintenance of bone mass in adult life. 
 In summary, MRTFA KO mice exhibited an osteoporotic phenotype with reduced 
bone mass in the trabecular femurs in both genders. This phenotype appears to be due to 
inhibited osteoblastogenesis. MRTFA appears to be an important regulator for 
maintaining bone mass in vivo.   
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Deletion of MRTFA promotes the differentiation of primary bone marrow MSCs to 
adipocytes versus osteoblasts. 
Introduction 
MSCs are pluripotent bone marrow stromal progenitors which possess the 
potential to differentiate into chondrocytes, adipocytes, myoblasts or osteoblasts when 
given the appropriate milieu of growth factors and extracellular microenvironment 
(Caplan and Bruder 2001) (Figure 1). However, an understanding of the underlying 
molecular mechanisms of the fate commitment of MSCs to different lineages is still 
incomplete.  
Based on previous studies (McBeath, Pirone et al. 2004, Xian, Wu et al. 2012) 
and the osteoporotic phenotype seen in the MRTFA KO mice, we hypothesize that the 
actin-MRTFA-SRF circuit is acting downstream of RhoA-ROCK pathway to regulate 
MSC fate commitment. Because the mouse model we used is a MRTFA global knock out, 
we have not yet been able to definitively confirm that the osteoporotic phenotype is 
caused by inappropriate fate switch of the MSCs in a cell autonomous manner. In this 
section, we isolated bone marrow MSCs from WT and MRTFA KO mice to determine 
whether the fate commitment of these cells is altered by the ablation of MRTFA using an 
established ex vivo system.  
The SRF inhibitor, CCG1423, is a small molecule acting downstream of the 
RhoA-ROCK pathway to inhibit MRTFA-dependent SRF target gene transcription 
(Evelyn, Wade et al. 2007). By treating the MSCs with CCG1423, we can determine 
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whether MRTFA-SRF-dependent transcriptional activity is important for MSC lineage 
commitment.  
 
Results 
The fate commitment of MSCs isolated from MRTFA KO mice shifted towards 
adipocytes over osteoblasts. 
Bone marrow derived MSCs isolated from MRTFA KO mice exhibited an 
enhanced capacity to differentiate into adipocytes in comparison to the MSCs from WT 
mice (Figure 21). The phase contrast microscopic images of the MSCs showed that the 
MRTFA KO cultures accumulated more lipid droplets during adipogenesis (Figure 21A). 
Furthermore, the mRNA and protein levels of several important adipogenic genes such as 
Pparg, Cepba, Adipoq and Fabp4 were significantly increased in the MRTFA KO cells 
relative to the controls (Figure 21B, C).  
Interestingly, mRNA levels of several brown fat genes including beta-3 
adrenergic receptor (Adrb3), peroxisome proliferator-activated receptor gamma co-
activator 1-α (Ppargc1a) and Ppargc1b also increased in the MRTFA KO cells. These 
findings are consistent with a recent study conducted by our group showing that MRTFA 
regulates the commitment of beige adipocytes. In fact, studies by others have identified a 
subset of brown fat genes in bone marrow fat and referred to it as yellow fat (Krings, 
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Rahman et al. 2012). Whether enhancement of these brown fat genes in the MRTFA KO 
mice contributes to the whole body metabolism deserves further investigation.   
100 
 
Figure 21. Bone marrow derived MSCs from MRTFA KO mice showed enhanced 
adipogenic differentiation. 
Femurs and tibiae were dissected from WT (n=3) and MRTFA KO mice (n=3). 
The bone marrow cavity contents were flushed out of these bones with MSC growth 
media. After the MSCs reach confluence, adipogenic inducers were added to the cells. 
Dexamethasone, IBMX, insulin, T3 and indomethacin were added for 2 days and T3 and 
insulin were supplemented in the growth media for another 8 days. The phase contrast 
microscopic images were acquired at day 10 of adipogenesis (A). The mRNA and protein 
samples were then extracted from these cells. Adipogenic gene expression was analyzed 
by RT-PCR using the corresponding primers Pparg, Cebpa, Plin, Adipoq, Fabp4, 
Ppargc1a, Ppargc1b and Adrb3. The mean relative levels (normalized to Gapdh mRNA 
levels) of the genes expression are shown in (C) with standard error (*p<0.05). 
Expression of adiponectin and C/EBPα in these differentiated MSCs were probed with 
western blots analysis as shown in C.  
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In contrast to WT MSCs, the MRTFA KO cells showed compromised 
osteoblastogenic differentiation with decreased bone nodule formation and mineral 
deposition (Figure 22A). Alizarin Red S staining was performed to visualize the calcific 
deposition in the differentiated WT and MRTFA KO MSCs (Figure 22B). Both male and 
female MRTFA KO MSCs had less mineral deposition as compared to the controls and 
this difference was more striking in the females.  The mRNA levels of several 
osteoblastogenic genes such as Runx2, Spp1, Bglap and Spock were reduced in 
differentiated MRTFA KO mice MSCs (Figure 22C). We hypothesize that the inhibition 
of these osteoblastogenic genes leads to the reduced mineral deposition during bone 
formation as described in the last section.   
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Figure 22. Osteoblastogenesis was attenuated in MRTFA KO mice bone marrow 
MSCs. 
The bone marrow derived MSCs were harvested as described in Figure 21. After 
the MSCs reached confluence, the cells were treated with osteoblastogenic inducers 
including L-ascorbic acid, β-glycerophosphate and dexamethasone. This osteo-inducing 
media were refreshed every 3 days until day 21 of differentiation. The phase-contrast 
images were acquired at day 21 of osteoblastogenesis (A). Then the differentiated cells 
were stained with 2% Alizarin Red S to visualize the mineral depositions in mature 
osteoblasts (B). The mRNA samples were extracted from MSCs at day 21 of 
osteoblastogenic differentiation. Osteoblastogenic genes were probed by RT-PCR using 
the following primers: Runx2, Alpl, Spp1, Spock and Bglap. The data are presented C as 
described in Figure 19 (*p<0.05).  
 
 
 
105 
 
Figure 22 
 
 
 
106 
 
 
 
 
 
 
 
 
 
107 
 
The SRF inhibitor CCG1423 attenuated osteoblastogenesis and promoted adipogenesis 
in bone marrow MSCs 
CCG1423 pre-treated MSCs (treated with CCG1423 for 2 days prior to 
adipogenic induction) had more lipid accumulation (Figure 23A) and increased mRNA 
levels of adipogenic genes such as Pparg, Cepba and Plin (Figure 23B). When CCG1423 
was added for the entire differentiation time frame, there was a similar degree of 
enhancement of adipogenesis (data not shown).   
On the other hand, when CCG1423 was added to the MSCs during 
osteoblastogenesis, bone nodule formation was inhibited (Figure 24A). Reduced mRNA 
levels of Alpl, Bglap and Spock genes also confirmed the inhibition (Figure 24B). When 
CCG1423 was only added to MSCs for 2 days prior to osteoblastogenic induction, there 
was no inhibitory effect on osteoblastogenic gene expression at day 21 of differentiation. 
It is likely that after 21 days of osteoblastogenesis, the initial reduction in SRF/MRTFA 
activity by CCG1423 recovered to levels permissive for osteoblastogenic gene expression. 
 These data also suggest that SRF/MRTFA activity is required throughout the 
osteoblastogenic process. In contrast, it appears that SRF/MRTFA activity only needs to 
be suppressed during the commitment phase of adipogenesis, unless differentiation itself 
inhibits the activity.   
In conclusion, the fate commitment of MSCs was regulated by the SRF/MRTFA 
activity. Inhibiting the SRF/MRTFA activity led to inhibition of osteoblastogenesis but 
enhancement of adipogenesis in WT MSCs.   
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Figure 23. The SRF inhibitor CCG1423 enhanced adipogenesis in WT bone marrow 
MSCs. 
Bone marrow MSCs were isolated from WT mice (n=3). DMSO (vehicle) or 1 
mM SRF inhibitor CCG1423 was added to the MSCs when the cells were sub-confluent. 
CCG1423 was then removed and the adipogenic inducers mentioned in Figure 21 were 
added at confluence. The phase-contrast images of the cells were captured at day 10 (A). 
The mRNA levels of adipogenic genes were measured by RT-PCR using primers for 
Pparg, Cebpa, Plin and Adipoq (B). The data is presented according to Figure 19 
(*p<0.05).   
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Figure 24. SRF inhibitor inhibited osteoblastogenesis in WT bone marrow MSCs. 
DMSO (vehicle) or 1 mM SRF inhibitor CCG1423 was added to the MSCs when 
the cells reached confluence, together with the osteoblastogenic inducers as described in 
Figure 22. The osteoblastogenic inducing media was refreshed every 3 days with either 
DMSO or CCG1423 for a total of 21 days. The phase-contrast images were captured at 
day 21 of differentiation (A). Osteoblastogenic gene mRNA levels were measured by 
RT-PCR using primers against Runx2, Alpl, Spp1, Bglap and Spock (B). That data is 
presented as in Figure 19 (*p<0.05).  
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Discussion 
 In this chapter, we discovered that the ablation of MRTFA in bone marrow MSCs 
inhibited osteoblastogenesis but enhance adipogenesis in a cell autonomous manner.  
Isolating and investigating the bone marrow MSCs helped to rule out the possibility that 
the osteoporotic phenotype seen in the MRTFA KO mice was caused entirely by 
systemic growth hormone defects (IGF1 and IGF1R). We speculate that the ablation of 
MRTFA and MRTFA-dependent SRF target genes altered the actin dynamics in the 
MSCs, which led to cytoskeletal re-organization, becoming more permissive for 
adipogenic rather than osteoblastogenic differentiation.  
 Evelyn showed that CCG1423 specifically inhibits SRF/MRTFA-induced target 
genes such as actin itself and regulators for actin dynamics and turnover (Evelyn, Wade 
et al. 2007). Despite the fact that CCG1423 was removed once the adipogenic induction 
was started, the adipogenesis was still increased in the WT MSCs. From this, we can 
infer that MRTFA/SRF regulated the MSCs fate commitment at a very early stage prior 
to morphological differentiation.  
 Although the bone marrow derived MSCs used in the aforementioned studies 
provided a useful ex vivo system to study MSC fate switch, the heterogeneity of these un-
sorted bone marrow cells might confound the interpretation of the results. It has been 
shown that only 0.01%-0.001% of the total bone marrow cells are MSCs (Pittenger, 
Mackay et al. 1999). Although the erythrocytes and unattached immune cells were 
removed by media change after the MSCs were attached (more than 70%-80% of the 
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total cells), there were still significant numbers of cells, presumably hematopoietic stem 
cells, immune cells, endothelial cells, fibroblasts and others in the mixed culture. Some of 
these cells might respond very differently to the growth factor treatment and confound 
the results obtained from these experiments. As seen in Figure 21 and 23, the percentage 
of increase in the mRNA levels of adipogenic genes is milder compared to the differences 
observed in the phase-contrast images of the cells. The undifferentiated non-MSCs might 
dilute the adipogenic gene mRNA signal detected by RT-PCR, thus lead to the 
inconsistencies in the results. This potentially confounding factor of this system should 
be taken into consideration during data interpretation and the MSCs should be further 
purified in future studies.  
In conclusion, we have showed that the ablation of MRTFA in the MSCs 
enhanced adipogenesis but inhibited osteoblastogenesis. Treating the WT MSCs with 
SRF inhibitor CCG1423 mimicked the effects of knocking out MRTFA by inhibiting 
osteoblastogenesis but enhancing adipogenesis.   
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MRTF/SRF signaling promotes osteogenesis and inhibits adipogenesis in MSC line 
C3H10T1/2 cells. 
Introduction 
Based on the results in the previous sections, we have concluded that MRTFA is 
important for maintaining bone mass in vivo due to its role in regulating the MSC fate 
switch between adipose and osteoblastic lineages. In this section, we document the 
changes of MRTFA, SRF and select target genes during adipogenesis.  C3H10T1/2 
MSCs stably over-expressing MRTFA, SRF and their dominant negative variants were 
used to manipulate the MRTFA/SRF activity in order to study the role of the actin-
MRTFA-SRF circuit in MSC fate determination.  
C3H/10T1/2 cells were originally derived from primary cells isolated from a 
whole C3H mouse embryo as described in a study published in 1973 (Reznikoff, Bertram 
et al. 1973). These cells possess the potential to differentiate into multiple lineages such 
as adipocytes, chondrocytes, osteoblasts and myoblasts, thus they are widely used for 
studying MSCs. Because the studies described earlier were conducted in heterogeneous 
bone marrow cells, the results might be confounded by the presence of other cells types 
in the bone marrow besides MSCs. Therefore, it is of interest to recapitulate these results 
in C3H10T1/2 cell lines over-expressing MRTFA, dominant negative MRTFA (DN-
MRTFA) to support the conclusions drawn earlier.  
Mikkelsen first identified SRF as a negative regulator of adipogenesis (Mikkelsen, 
Xu et al. 2010). Chen has since showed that SRF regulates bone formation via IGF-1 and 
Runx2 (Chen, Yuan et al. 2012). Based on the aforementioned studies, we hypothesized 
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that SRF promotes osteoblastogenesis but inhibits adipogenesis in the MSCs through the 
same mechanisms as described in Chapters I and II. This chapter serves to prove this 
hypothesis in C3H/10T1/2 cell lines over-expressing SRF and dominant negative SRF 
(DN-SRF).  
 
MRTFA, SRF and their target genes are down-regulated during adipogenesis 
Figure 25 and 27 shown in this chapter have been published in McDonald and Li 
et al. 2015 (McDonald, Li et al. 2015). Permission to include these figures in this thesis 
was acquired from Cell Journal.   
During the adipogenic differentiation of C3H10T1/2 cells, Mrtfa, Mrtfb, Srf and 
their select target genes including Acta, Col1a1 and Col3a1 are all down-regulated, 
thereby allowing the cells to adopt a round morphology for promoting lipid accumulation 
as shown in Figure 25A and B. This down-regulation of genes happened at an early stage 
of adipogenesis prior to morphological differentiation. The mRNA levels of these genes 
decreased at least 60% as compared to baseline between day 0 and day 1 of adipogenesis 
and this significant reduction continued until day 2 as shown in Figure 25A and B. The 
levels of these genes remained low throughout adipogenic differentiation and lipid 
droplets accumulated in the maturing adipocytes. MRTFA and SRF appeared to be 
negative regulators for adipogenesis. The down-regulation of MRTFA, SRF and their 
target genes is associated with the dramatic reorganization of cytoskeleton, which is 
required for proper adipocyte maturation (Spiegelman and Farmer 1982).  
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Figure 25. MRTFA, SRF and their select target genes were down-regulated during 
adipogenesis. 
C3H/10T1/2 cells were induced for adipogenic differentiation upon confluence 
with growth media containing dexamethasone, IBMX, insulin, T3 and indomethacin for 2 
days. The cells were then maintained in growth media supplemented with T3 and insulin 
for another 6 days. mRNA and protein samples (n=3) were extracted at different time 
points at day 0 (D0), day 1 (D1), day 2 (D2), day 4 (D4), day 6 (D6) and day 8 (D8) for 
RT-PCR (A) and western blot analysis (B). The genes probed in A are Mrtfa, Mrtfb, Srf, 
Acta, Col1a1, Col3a1, Fabp4 and Ucp1. The fold changes of these genes (shown with 
standard error) were normalized to Gapdh mRNA levels and the mean value of day 0 
samples was set at 1. The protein levels of MRTFA, SRF, SMA and FABP4 are shown in 
B.  
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MRTFA and SRF promotes osteogenesis and inhibits adipogenesis. 
The C3H/10T1/2 stable cell lines over-expressing MRTFA, SRF and their 
dominant negative variants were generated by retroviral infection as described in the 
Materials and Methods (Luchsinger, Patenaude et al. 2011, Wang, Prakash et al. 2012). 
Western blot analysis was performed on these cells to confirm successful stable over-
expression of the relevant proteins. MRTFA and FLAG-tag levels were probed. The 
MRTFA band migrates as a 150 kilodalton (kDa) band and the SRF band (FLAG-tagged) 
at approximately 50 kDa (Figure 26), sizes which are consistent with their known 
molecular weights and the time course results in Figure 26. DN-MRTFA band (FLAG-
tagged) migrated as a 70 kDa band and DN-SRF band (FLAG-tagged) at approximately 
30 kDa (Figure 26). The sizes of these bands are also consistent with the numbers of 
amino acids in these dominant negative variants (truncated forms without the 
transactivation domains). Although the mRNA and the protein level of MRTFA was 
significantly increased in the MRTFA over-expressing cells, we were unable to detect 
any signal for FLAG-tag in these cells.  
Over-expression of MRTFA or SRF inhibited adipogenesis with reduced lipid 
droplet accumulation and inhibited adipogenic genes expression; whereas the over-
expression of DN-MRTFA or DN-SRF enhanced adipogenesis. As shown in Figure 27A, 
MRTFA or SRF over-expressing MSCs had significantly less lipid-laden cells, while the 
cultures of dominant negative variants MSCs had many more mature adipocytes (Figure 
27A). These observations were confirmed by the mRNA levels of adipogenic genes in the 
mentioned cell lines. Over-expression of either MRTFA or SRF inhibited mRNA 
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accumulation of Pparg, Cebpa, Plin, Adipoq and Fabp4 (Figure 27B); whereas over-
expression of their dominant negative forms increased expression of some of these genes 
(Figure 27B). The consequent changes in protein levels of C/EBPα, perilipin and 
adiponectin were consistent with these results (Figure 27C).  
Interestingly, brown fat genes fatty acid binding protein 3 (FABP3), cell death 
activator CIDE-A (Cidea), ELOVL fatty acid elongase 3 (Elovl3) and cytochrome c 
oxidase polypepetide 7A1 (Cox7a1) (Figure 27D) were also significantly inhibited in the 
MRTFA or SRF over-expressing cells during BMP7-induced adipogenesis. These results 
are consistent with the findings in the earlier study on bone marrow MSCs and our 
previous study showing that MRTFA KO adipose stromal fraction cells have enhanced 
brown fat genes (McDonald, Li et al. 2015).  
The over-expression of MRTFA, SRF or their dominant negative variants, on the 
other hand, resulted in very different cell shapes for the MSCs during osteoblastogenesis 
(Figure 28A). The MRTFA or SRF over-expressing MSCs exhibited spread and 
elongated shapes in response to the osteoblastogenic inducers (Figure 28A).  In contrast, 
the shapes of the cells over-expressing either DN-MRTFA or DN-SRF were rounder and 
more irregular (Figure 28A). These observed changes in the cell shapes correlated with 
changes in osteoblastogenic mRNA levels.  MRTFA or SRF over-expression enhanced 
osteoblastogenic genes such as Spp1 and Bglap (Figure 28B); while dominant negative 
variants inhibited the expression of these genes (Figure 28C).    
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Figure 26. Over-expression of MRTFA, SRF and their dominant negative variants 
in C3H/10T1/2 cells. 
 The stable C3H/10T1/2 cells lines were harvested for western blot analysis to 
confirm the successful over-expression of MRTFA, SRF and their dominant negative 
variants. Probes against MRTFA and FLAG-tag were used for these samples. The 
MRTFA band is around 150 kDa and the SRF band is around 50 kDa. DN-MRTFA 
FLAG tag band is around 70 kDa and DN-SRF FLAG tag band is around 30 kDa.   
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Figure 27. Over-expression of MRTFA and SRF in C3H/10T1/2 cells inhibits 
adipogenesis, while over-expression of dominant negative variants have the opposite 
effect. 
The C3H/10T1/2 stable cell lines over-expressing MRTFA, SRF, DN-MRTFA 
and DN-SRF were induced for adipogenic differentiation as described in Figure 25. 
Except that BMP7 was added to the cells in D for three days prior to adipogenic 
induction to facilitate the induction of brown fat genes. The phase-contrast microscopic 
images were captured before harvesting on day 8 of adipogenesis (A). mRNA and 
proteins samples (n=3) were then extracted from these cells for RT-PCR (B, D) and 
western blot (C) analysis. The data is presented as in Figure 25. Student’s T-test was 
performed to assess the statistical significance (*p<0.05, **p<0.01). 
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Figure 28. Over-expression of MRTFA and SRF in C3H/10T1/2 cells enhances 
osteoblastogenesis, while over-expression of the dominant negative variants have the 
opposite effect. 
The C3H/10T1/2 stable cell lines over-expressing MRTFA, SRF, DN-MRTFA 
and DN-SRF were induced with osteoblastogenic media containing β-glycerophosphate, 
ascorbic acid and dexamethasone for 21 days upon reaching confluence.  The phase-
contrast images were captured at day 7 of differentiation (A). mRNA samples (n=3) were 
extracted from these cells at day 21 of differentiation for RT-PCR (B, C) analysis. The 
data is presented according to Figure 25 (*p<0.05).   
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Discussion 
In this chapter, we demonstrated that MRTFA, SRF and their select target genes 
were down-regulated during adipogenesis at an early stage. Over-expressing MRTFA or 
SRF inhibited adipogenesis by reducing adipogenic gene expression, including some of 
the brown fat genes. In contrast, over-expressing DN-MRTFA or DN-SRF promoted 
adipogenesis by enhancing adipogenic genes. In contrast, MRTFA or SRF over-
expression increased osteoblast differentiation while the dominant negative variants had 
the opposite effects.  
 The down-regulation of MRTFA, MRTFB, SRF and their targets genes such as 
SMA, Collagen1α1 and Collagen3α1 occurred mostly from days 0 to 2 of adipogenic 
differentiation. The degree of reduction of these genes was significant, averaging about 
60% to 80% reduction as compared to the baseline levels. The timing of the down-
regulation for these genes suggests that inhibition of the MRTFA/SRF pathway is 
necessary for the proper maturation of pre-adipocytes. The similar patterns of gene 
expression for MRTFA and MRTFB indicate potentially overlapping functions for these 
two factors during adipogenesis. Therefore, in the results described in chapters the last 2 
sections, MRTFB activity might be functionally compensating for the loss of MRTFA 
thus minimizing the severity of the observed osteoporotic phenotype.  
 By establishing C3H/10T1/2 stable over-expression cell lines, we manipulated the 
transcriptional activity of MRTFA/SRF to study the role of this pathway in MSC 
commitment. MRTFA and SRF over-expression inhibited adipogenesis in these MSCs 
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while the dominant negative variants had the opposite effect, which is consistent with 
published findings (Nobusue, Onishi et al. 2014, McDonald, Li et al. 2015). MRTFA and 
SRF appear to be negative regulators for adipogenesis. We maintain that MRTFA and 
SRF may be involved in the regulation of both the early fate commitment to adipose 
lineage as well as the morphological differentiation. The exact mechanisms of these 
effects will be further investigated by other group members in future studies.  
 MRTFA and SRF over-expression enhanced osteoblastogenesis in MSCs whereas 
their dominant negative variants had the opposite effects. We speculate that the 
enhancement of MRTFA/SRF pathway facilitates the necessary cytoskeletal 
reorganization to accommodate to osteoblast differentiation. Interestingly, there was 
adipocyte formation in both DN-MRTFA and DN-SRF over-expression cell lines even 
when they were constantly induced with osteoblastogenic factors. In fact, we were still 
able to detect certain adipogenic proteins such as adiponectin and FABP4 in these cells. 
Ablation of the MRTFA/SRF pathway was sufficient to bypass the osteoblastogenic cues 
in the growth media and drove the MSCs differentiation into adipocytes through 
alteration of their cytoskeletal signaling.  
Summary 
We propose that the actin-MRTFA-SRF circuit acts downstream of Rho-ROCK 
signaling to promote osteoblastogenesis and inhibit adipogenesis in the MSCs. As 
demonstrated by McBeath (McBeath, Pirone et al. 2004), when activated by mechanical 
tension, Rho-ROCK signaling activates downstream effectors to promote the 
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incorporation of G-actin to F-actin. MRTFA bound with G-actin is released for nuclear 
translocation and subsequent co-activation of SRF target genes. We hypothesize that the 
activation of these genes promotes a spreading and elongated cell shape, which primes 
the MSCs for osteoblastogenesis. In contrast, when the activation of these genes is 
inhibited due to MRTFA ablation, the MSCs adopt a rounded shape which is permissive 
for adipogenesis (Figure 29). 
This study identifies MRTFA as a crucial regulator of skeletal homeostasis via 
regulating the balance between adipogenic and osteoblastogenic differentiation in the 
MSCs, and thus holds promise as a potential target for therapeutic intervention for 
osteoporosis.  
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Figure 29. A model of actin-MRTFA-SRF circuit regulating the MSC fate 
commitment. 
This thesis showed that the actin-MRTFA-SRF circuit is acting downstream of 
Rho-ROCK signaling to promote osteoblastogenesis and inhibit adipogenesis in the 
MSCs (described in the summary section).  
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FUTURE DIRECTIONS 
The mechanisms behind the fate divergence of MSCs in response to BMP 
signaling (a pathway that positively regulates both adipogenesis and osteoblastogenesis) 
is still poorly understood. It appears that the orchestration of various pathways will 
jointly dictate which transcriptional cascades will be activated by BMPs (Kang et al., 
2009). Whether cytoskeletal signaling is involved in BMP-mediated MSCs fate 
divergence is worth further investigation. Using the MRTFA KO mice, MSCs and 
C3H/10T1/2 over-expression cell lines, whether BMPs will preferably activate 
adipogenesis versus osteoblastogenesis program in the MRTFA KO MSCs will be 
studied.  
 Investigation into the role of MRTFA-dependent SRF target genes in the 
regulation of early MSCs commitment is planned for follow-up studies by others in the 
Farmer laboratory.  The target genes co-activated by MRTFs are mostly cell contractile 
proteins and regulators for actin related proteins (Olson et al., 2010).  Genes involved in 
the regulation of actin dynamics include actin itself, regulators of actin turnover and 
regulators of actin dynamics. We hypothesize that these target genes downstream of 
MRTFA play important roles in regulating the MSCs commitment either directly or 
indirectly and this regulation appears to happen prior to the morphological differentiation.   
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